1
|
Evans JMM, Young JJ, Mutch H, Blunsum A, Quinn J, Lowe DJ, Ho A, Marsh K, Mokogwu D. Implementation and evaluation of a SARI surveillance system in a tertiary hospital in Scotland in 2021/2022. Public Health 2024; 232:114-120. [PMID: 38772199 DOI: 10.1016/j.puhe.2024.04.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Revised: 04/09/2024] [Accepted: 04/10/2024] [Indexed: 05/23/2024]
Abstract
OBJECTIVE To set up and evaluate a new surveillance system for severe acute respiratory infection (SARI) in Scotland. STUDY DESIGN Cross-sectional study and evaluation of surveillance system. METHODS The SARI case definition comprised patients aged 16 years or over with an acute respiratory illness presentation requiring testing for influenza and SARS-CoV-2 and hospital admission. Data were collected from SARI cases by research nurses in one tertiary teaching hospital using a bespoke data collection tool from November 2021 to May 2022. Descriptive analyses of SARI cases were carried out. The following attributes of the surveillance system were evaluated according to Centers for Disease Control and Prevention (CDC) guidelines: stability, data quality, timeliness, positive predictive value, representativeness, simplicity, acceptability and flexibility. RESULTS The final surveillance dataset comprised 1163 records, with cases peaking in ISO week 50 (week ending 19/12/2021). The system produced a stable stream of surveillance data, with the proportion of SARI records with sufficient information for effective surveillance increasing from 65.4% during the first month to 87.0% over time. Similarly, the proportion where data collection was completed promptly was low initially, but increased to 50%-65% during later periods. CONCLUSION SARI surveillance was successfully established in one hospital, but for a national system, additional sentinel hospital sites across Scotland, with flexibility to ensure consistently high data completeness and timeliness are needed. Data collection should be automated where possible, and demands on clinicians minimised. SARI surveillance should be embedded and resourced as part of a national respiratory surveillance strategy.
Collapse
Affiliation(s)
- J M M Evans
- Public Health Scotland, Glasgow, United Kingdom.
| | - J J Young
- Public Health Scotland, Glasgow, United Kingdom
| | - H Mutch
- Public Health Scotland, Glasgow, United Kingdom
| | - A Blunsum
- Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, United Kingdom
| | - J Quinn
- Emergency Department, Queen Elizabeth University Hospital, Glasgow, United Kingdom
| | - D J Lowe
- Emergency Department, Queen Elizabeth University Hospital, Glasgow, United Kingdom; School of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom
| | - A Ho
- Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, United Kingdom; Medical Research Council-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom
| | - K Marsh
- Public Health Scotland, Glasgow, United Kingdom
| | - D Mokogwu
- Public Health Scotland, Glasgow, United Kingdom
| |
Collapse
|
2
|
Park S, Liu H, Quinn J, Lapidus SH, Zhang Y, Trask SE, Wang C, Key B, Dogan F. Surface and Bulk Stabilization of Silicon Anodes with Mixed-Multivalent Additives: Ca(TFSI) 2 and Mg(TFSI) 2. ACS Appl Mater Interfaces 2024. [PMID: 38621292 DOI: 10.1021/acsami.3c17578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/17/2024]
Abstract
Silicon is drawing attention as an emerging anode material for the next generation of lithium-ion batteries due to its higher capacity compared with commercial graphite. However, silicon anions formed during lithiation are highly reactive with binder and electrolyte components, creating an unstable SEI layer and limiting the calendar life of silicon anodes. The reactivity of lithium silicide and the formation of an unstable SEI layer are mitigated by utilizing a mixture of Ca and Mg multivalent cations as an electrolyte additive for Si anodes to improve their calendar life. The effect of mixed salts on the bulk and surface of the silicon anodes was studied by multiple structural characterization techniques. Ca and Mg ions in the electrolyte formed relatively thermodynamically stable quaternary Li-Ca-Mg-Si Zintl phases in an in situ fashion and a more stable and denser SEI layer on the Si particles. These in turn protect silicon particles against side reactions with electrolytes in a coin cell. The full cell with the mixed cation electrolyte demonstrates enhanced calendar life performance with lower measured current and current leakage in comparison to that of the baseline electrolyte due to reduced side reactions. Electron microscopy, HR-XRD, and solid-state NMR results showed that electrodes with mixed cations tended to have less cracking on the electrode surface, and the presence of mixed cations enhances cation migration and formation of quaternary Zintl phases stabilizing the bulk and forming a more stable SEI in comparison to baseline electrolyte and electrolyte with single multivalent cations.
Collapse
Affiliation(s)
- Sohyun Park
- Chemical Sciences and Engineering Division, Argonne National Laboratory, Lemont, Illinois 60439, United States
| | - Haoyu Liu
- Chemical Sciences and Engineering Division, Argonne National Laboratory, Lemont, Illinois 60439, United States
| | - Joseph Quinn
- Energy and Environment Directorate, Pacific Northwest National Laboratory, Richland, Washington 99354, United States
| | - Saul H Lapidus
- X-ray Science Division, Advanced Photon Source, Argonne National Laboratory, Lemont, Illinois 60439, United States
| | - Yunya Zhang
- Chemical Sciences and Engineering Division, Argonne National Laboratory, Lemont, Illinois 60439, United States
| | - Stephen E Trask
- Chemical Sciences and Engineering Division, Argonne National Laboratory, Lemont, Illinois 60439, United States
| | - Chongmin Wang
- Energy and Environment Directorate, Pacific Northwest National Laboratory, Richland, Washington 99354, United States
| | - Baris Key
- Chemical Sciences and Engineering Division, Argonne National Laboratory, Lemont, Illinois 60439, United States
| | - Fulya Dogan
- Chemical Sciences and Engineering Division, Argonne National Laboratory, Lemont, Illinois 60439, United States
| |
Collapse
|
3
|
McGarry A, Rosanbalm S, Leinonen M, Olanow CW, To D, Bell A, Lee D, Chang J, Dubow J, Dhall R, Burdick D, Parashos S, Feuerstein J, Quinn J, Pahwa R, Afshari M, Ramirez-Zamora A, Chou K, Tarakad A, Luca C, Klos K, Bordelon Y, St Hiliare MH, Shprecher D, Lee S, Dawson TM, Roschke V, Kieburtz K. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2024; 23:37-45. [PMID: 38101901 DOI: 10.1016/s1474-4422(23)00378-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Revised: 09/27/2023] [Accepted: 09/28/2023] [Indexed: 12/17/2023]
Abstract
BACKGROUND Converging lines of evidence suggest that microglia are relevant to Parkinson's disease pathogenesis, justifying exploration of therapeutic agents thought to attenuate pathogenic microglial function. We sought to test the safety and efficacy of NLY01-a brain-penetrant, pegylated, longer-lasting version of exenatide (a glucagon-like peptide-1 receptor agonist) that is believed to be anti-inflammatory via reduction of microglia activation-in Parkinson's disease. METHODS We report a 36-week, randomised, double-blind, placebo-controlled study of NLY01 in participants with early untreated Parkinson's disease conducted at 58 movement disorder clinics in the USA. Participants meeting UK Brain Bank or Movement Disorder Society research criteria for Parkinson's disease were randomly allocated (1:1:1) to one of two active treatment groups (2·5 mg or 5·0 mg NLY01) or matching placebo, based on a central computer-generated randomisation scheme using permuted block randomisation with varying block sizes. All participants, investigators, coordinators, study staff, and sponsor personnel were masked to treatment assignments throughout the study. The primary efficacy endpoint for the primary analysis population (defined as all randomly assigned participants who received at least one dose of study drug) was change from baseline to week 36 in the sum of Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts II and III. Safety was assessed in the safety population (all randomly allocated participants who received at least one dose of the study drug) with documentation of adverse events, vital signs, electrocardiograms, clinical laboratory assessments, physical examination, and scales for suicidality, sleepiness, impulsivity, and depression. This trial is complete and registered at ClinicalTrials.gov, NCT04154072. FINDINGS The study took place between Jan 28, 2020, and Feb 16, 2023. 447 individuals were screened, of whom 255 eligible participants were randomly assigned (85 to each study group). One patient assigned to placebo did not receive study treatment and was not included in the primary analysis. At 36 weeks, 2·5 mg and 5·0 mg NLY01 did not differ from placebo with respect to change in sum scores on MDS-UPDRS parts II and III: difference versus placebo -0·39 (95% CI -2·96 to 2·18; p=0·77) for 2·5 mg and 0·36 (-2·28 to 3·00; p=0·79) for 5·0 mg. Treatment-emergent adverse events were similar across groups (reported in 71 [84%] of 85 patients on 2·5 mg NLY01, 79 [93%] of 85 on 5·0 mg, and 73 [87%] of 84 on placebo), with gastrointestinal disorders the most commonly observed class in active groups (52 [61%] for 2·5 mg, 64 [75%] for 5·0 mg, and 30 [36%] for placebo) and nausea the most common event overall (33 [39%] for 2·5 mg, 49 [58%] for 5·0 mg, and 16 [19%] for placebo). No deaths occurred during the study. INTERPRETATION NLY01 at 2·5 and 5·0 mg was not associated with any improvement in Parkinson's disease motor or non-motor features compared with placebo. A subgroup analysis raised the possibility of motor benefit in younger participants. Further study is needed to determine whether these exploratory observations are replicable. FUNDING D&D Pharmatech-Neuraly.
Collapse
Affiliation(s)
- Andrew McGarry
- Cooper Medical School at Rowan University, Camden, NJ, USA; Clintrex Research Corporation, Sarasota, FL, USA.
| | | | | | | | - Dennis To
- D&D Pharmatech - Neuraly, Gaithersburg, MD, USA
| | - Adam Bell
- D&D Pharmatech - Neuraly, Gaithersburg, MD, USA
| | - Daniel Lee
- D&D Pharmatech - Neuraly, Gaithersburg, MD, USA
| | | | - Jordan Dubow
- Clintrex Research Corporation, Sarasota, FL, USA
| | - Rohit Dhall
- University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - Daniel Burdick
- Booth Gardner Parkinson's Care Center, Kirkland, WA, USA
| | | | - Jeanne Feuerstein
- Neurosciences Center at UC Health University of Colorado Hospital, Aurora, CO, USA
| | - Joseph Quinn
- Oregon Health and Sciences University, Portland, OR, USA
| | - Rajesh Pahwa
- University of Kansas Medical Center, Kansas City, KS, USA
| | | | | | - Kelvin Chou
- University of Michigan Medical Center, Ann Arbor, MI, USA
| | | | | | - Kevin Klos
- The Movement Disorder Clinic of Oklahoma, Tulsa, OK, USA
| | - Yvette Bordelon
- University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA
| | | | | | - Seulki Lee
- D&D Pharmatech - Neuraly, Gaithersburg, MD, USA
| | - Ted M Dawson
- Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | | | | |
Collapse
|
4
|
Swan D, Comerford C, Quinn J. Venous thromboembolism in multiple myeloma: Increasing evidence in support of direct oral anticoagulants. Br J Haematol 2023; 203:351-352. [PMID: 37581247 DOI: 10.1111/bjh.19056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 08/08/2023] [Accepted: 08/09/2023] [Indexed: 08/16/2023]
Abstract
Venous thromboembolism (VTE) continues to cause significant morbidity and excess mortality in patients with multiple myeloma. The report by Costa and colleagues demonstrates superiority of direct oral anticoagulants over aspirin in terms of VTE prevention, without increased bleeding complications seen. Commentary on: Costa et al. Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: A systematic review and updated meta-analysis. Br J Haematol 2023;203:395-403.
Collapse
Affiliation(s)
- D Swan
- RCSI Beaumont Cancer Centre, Dublin, Ireland
| | - C Comerford
- RCSI Beaumont Cancer Centre, Dublin, Ireland
- Irish Centre of Vascular Biology, School of Pharmacy and Biomolecular Science, RCSI, Dublin, Ireland
| | - J Quinn
- RCSI Beaumont Cancer Centre, Dublin, Ireland
| |
Collapse
|
5
|
Quinn J, Wu B, Xu Y, Engelhard MH, Xiao J, Wang C. Tracking the Oxidation of Silicon Anodes Using Cryo-EELS upon Battery Cycling. ACS Nano 2022; 16:21063-21070. [PMID: 36520937 DOI: 10.1021/acsnano.2c08777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
Silicon is a high-capacity material for the anode of a rechargeable lithium-ion battery. One of the fundamental challenges for using Si in anodes is capacity fading, which has been revealed to be partially associated with the interfacial instability between the Si and liquid electrolyte due to the large volume swing of Si upon charging and discharging. Smart nanoscale design concepts, either presynthesized or formed in situ, have led to the mitigation of the detrimental factors associated with the volume swing of Si. However, it has never been clear how the chemical state of Si evolves and contributes to the capacity fading upon battery cycling. Here, we use cryo-electron energy loss spectroscopy to directly monitor, at a subnanometer scale, the chemical evolution of Si upon battery cycling. We discover that during the cycling process Si particles are progressively oxidized to form SiO2, which is initiated from the particle surface and gradually penetrates toward the interior of the particle, directly contributing to the capacity fading. Possible mechanisms of Si oxidation are postulated. We further show how the cycling stability can be improved by an electrolyte additive to form an effective passivation layer, representatively, even a small concentration of fluoroethylene carbonate causes the formation of an LiF layer on the Si nanoparticle surface that prevents Si oxidation and improves cycling stability. The present work unveils Si oxidation as a previously unrecognized factor that contributes to capacity fading, therefore providing insight into the design of anodes with Si-based materials.
Collapse
Affiliation(s)
- Joseph Quinn
- Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington99352, United States
| | - Bingbin Wu
- Energy and Environment Directorate, Pacific Northwest National Laboratory, Richland, Washington99354, United States
| | - Yaobin Xu
- Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington99352, United States
| | - Mark H Engelhard
- Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington99352, United States
| | - Jie Xiao
- Energy and Environment Directorate, Pacific Northwest National Laboratory, Richland, Washington99354, United States
| | - Chongmin Wang
- Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington99352, United States
| |
Collapse
|
6
|
Nadarajah R, Ludman P, Appelman Y, Brugaletta S, Budaj A, Bueno H, Huber K, Kunadian V, Leonardi S, Lettino M, Milasinovic D, Gale CP, Budaj A, Dagres N, Danchin N, Delgado V, Emberson J, Friberg O, Gale CP, Heyndrickx G, Iung B, James S, Kappetein AP, Maggioni AP, Maniadakis N, Nagy KV, Parati G, Petronio AS, Pietila M, Prescott E, Ruschitzka F, Van de Werf F, Weidinger F, Zeymer U, Gale CP, Beleslin B, Budaj A, Chioncel O, Dagres N, Danchin N, Emberson J, Erlinge D, Glikson M, Gray A, Kayikcioglu M, Maggioni AP, Nagy KV, Nedoshivin A, Petronio AP, Roos-Hesselink JW, Wallentin L, Zeymer U, Popescu BA, Adlam D, Caforio ALP, Capodanno D, Dweck M, Erlinge D, Glikson M, Hausleiter J, Iung B, Kayikcioglu M, Ludman P, Lund L, Maggioni AP, Matskeplishvili S, Meder B, Nagy KV, Nedoshivin A, Neglia D, Pasquet AA, Roos-Hesselink JW, Rossello FJ, Shaheen SM, Torbica A, Gale CP, Ludman PF, Lettino M, Bueno H, Huber K, Leonardi S, Budaj A, Milasinovic (Serbia) D, Brugaletta S, Appelman Y, Kunadian V, Al Mahmeed WAR, Kzhdryan H, Dumont C, Geppert A, Bajramovic NS, Cader FA, Beauloye C, Quesada D, Hlinomaz O, Liebetrau C, Marandi T, Shokry K, Bueno H, Kovacevic M, Crnomarkovic B, Cankovic M, Dabovic D, Jarakovic M, Pantic T, Trajkovic M, Pupic L, Ruzicic D, Cvetanovic D, Mansourati J, Obradovic I, Stankovic M, Loh PH, Kong W, Poh KK, Sia CH, Saw K, Liška D, Brozmannová D, Gbur M, Gale CP, Maxian R, Kovacic D, Poznic NG, Keric T, Kotnik G, Cercek M, Steblovnik K, Sustersic M, Cercek AC, Djokic I, Maisuradze D, Drnovsek B, Lipar L, Mocilnik M, Pleskovic A, Lainscak M, Crncic D, Nikojajevic I, Tibaut M, Cigut M, Leskovar B, Sinanis T, Furlan T, Grilj V, Rezun M, Mateo VM, Anguita MJF, Bustinza ICM, Quintana RB, Cimadevilla OCF, Fuertes J, Lopez F, Dharma S, Martin MD, Martinez L, Barrabes JA, Bañeras J, Belahnech Y, Ferreira-Gonzalez I, Jordan P, Lidon RM, Mila L, Sambola A, Orvin K, Sionis A, Bragagnini W, Cambra AD, Simon C, Burdeus MV, Ariza-Solé A, Alegre O, Alsina M, Ferrando JIL, Bosch X, Sinha A, Vidal P, Izquierdo M, Marin F, Esteve-Pastor MA, Tello-Montoliu A, Lopez-Garcia C, Rivera-Caravaca JM, Gil-Pérez P, Nicolas-Franco S, Keituqwa I, Farhan HA, Silva L, Blasco A, Escudier JM, Ortega J, Zamorano JL, Sanmartin M, Pereda DC, Rincon LM, Gonzalez P, Casado T, Sadeghipour P, Lopez-Sendon JL, Manjavacas AMI, Marin LAM, Sotelo LR, Rodriguez SOR, Bueno H, Martin R, Maruri R, Moreno G, Moris C, Gudmundsdottir I, Avanzas P, Ayesta A, Junco-Vicente A, Cubero-Gallego H, Pascual I, Sola NB, Rodriguez OA, Malagon L, Martinez-Basterra J, Arizcuren AM, Indolfi C, Romero J, Calleja AG, Fuertes DG, Crespín Crespín M, Bernal FJC, Ojeda FB, Padron AL, Cabeza MM, Vargas CM, Yanes G, Kitai T, Gonzalez MJG, Gonzalez Gonzalez J, Jorge P, De La Fuente B, Bermúdez MG, Perez-Lopez CMB, Basiero AB, Ruiz AC, Pamias RF, Chamero PS, Mirrakhimov E, Hidalgo-Urbano R, Garcia-Rubira JC, Seoane-Garcia T, Arroyo-Monino DF, Ruiz AB, Sanz-Girgas E, Bonet G, Rodríguez-López J, Scardino C, De Sousa D, Gustiene O, Elbasheer E, Humida A, Mahmoud H, Mohamed A, Hamid E, Hussein S, Abdelhameed M, Ali T, Ali Y, Eltayeb M, Philippe F, Ali M, Almubarak E, Badri M, Altaher S, Alla MD, Dellborg M, Dellborg H, Hultsberg-Olsson G, Marjeh YB, Abdin A, Erglis A, Alhussein F, Mgazeel F, Hammami R, Abid L, Bahloul A, Charfeddine S, Ellouze T, Canpolat U, Oksul M, Muderrisoglu H, Popovici M, Karacaglar E, Akgun A, Ari H, Ari S, Can V, Tuncay B, Kaya H, Dursun L, Kalenderoglu K, Tasar O, Kalpak O, Kilic S, Kucukosmanoglu M, Aytekin V, Baydar O, Demirci Y, Gürsoy E, Kilic A, Yildiz Ö, Arat-Ozkan A, Sinan UY, Dagva M, Gungor B, Sekerci SS, Zeren G, Erturk M, Demir AR, Yildirim C, Can C, Kayikcioglu M, Yagmur B, Oney S, Xuereb RG, Sabanoglu C, Inanc IH, Ziyrek M, Sen T, Astarcioglu MA, Kahraman F, Utku O, Celik A, Surmeli AO, Basaran O, Ahmad WAW, Demirbag R, Besli F, Gungoren F, Ingabire P, Mondo C, Ssemanda S, Semu T, Mulla AA, Atos JS, Wajid I, Appelman Y, Al Mahmeed WAR, Atallah B, Bakr K, Garrod R, Makia F, Eldeeb F, Abdekader R, Gomaa A, Kandasamy S, Maruthanayagam R, Nadar SK, Nakad G, Nair R, Mota P, Prior P, Mcdonald S, Rand J, Schumacher N, Abraheem A, Clark M, Coulding M, Qamar N, Turner V, Negahban AQ, Crew A, Hope S, Howson J, Jones S, Lancaster N, Nicholson A, Wray G, Donnelly P, Gierlotka M, Hammond L, Hammond S, Regan S, Watkin R, Papadopoulos C, Ludman P, Hutton K, Macdonald S, Nilsson A, Roberts S, Monteiro S, Garg S, Balachandran K, Mcdonald J, Singh R, Marsden K, Davies K, Desai H, Goddard W, Iqbal N, Chalil S, Dan GA, Galasko G, Assaf O, Benham L, Brown J, Collins S, Fleming C, Glen J, Mitchell M, Preston S, Uttley A, Radovanovic M, Lindsay S, Akhtar N, Atkinson C, Vinod M, Wilson A, Clifford P, Firoozan S, Yashoman M, Bowers N, Chaplin J, Reznik EV, Harvey S, Kononen M, Lopesdesousa G, Saraiva F, Sharma S, Cruddas E, Law J, Young E, Hoye A, Harper P, Balghith M, Rowe K, Been M, Cummins H, French E, Gibson C, Abraham JA, Hobson S, Kay A, Kent M, Wilkinson A, Mohamed A, Clark S, Duncan L, Ahmed IM, Khatiwada D, Mccarrick A, Wanda I, Read P, Afsar A, Rivers V, Theobald T, Cercek M, Bell S, Buckman C, Francis R, Peters G, Stables R, Morgan M, Noorzadeh M, Taylor B, Twiss S, Widdows P, Brozmannová D, Wilkinson V, Black M, Clark A, Clarkson N, Currie J, George L, Mcgee C, Izzat L, Lewis T, Omar Z, Aytekin V, Phillips S, Ahmed F, Mackie S, Oommen A, Phillips H, Sherwood M, Aleti S, Charles T, Jose M, Kolakaluri L, Ingabire P, Karoudi RA, Deery J, Hazelton T, Knight A, Price C, Turney S, Kardos A, Williams F, Wren L, Bega G, Alyavi B, Scaletta D, Kunadian V, Cullen K, Jones S, Kirkup E, Ripley DP, Matthews IG, Mcleod A, Runnett C, Thomas HE, Cartasegna L, Gunarathne A, Burton J, King R, Quinn J, Sobolewska J, Munt S, Porter J, Christenssen V, Leng K, Peachey T, Gomez VN, Temple N, Wells K, Viswanathan G, Taneja A, Cann E, Eglinton C, Hyams B, Jones E, Reed F, Smith J, Beltrano C, Affleck DC, Turner A, Ward T, Wilmshurst N, Stirrup J, Brunton M, Whyte A, Smith S, Murray V, Walker R, Novas V, Weston C, Brown C, Collier D, Curtis K, Dixon K, Wells T, Trim F, Ghosh J, Mavuri M, Barman L, Dumont C, Elliott K, Harrison R, Mallinson J, Neale T, Smith J, Toohie J, Turnbull A, Parker E, Hossain R, Cheeseman M, Balparda H, Hill J, Hood M, Hutchinson D, Mellows K, Pendlebury C, Storey RF, Barker J, Birchall K, Denney H, Housley K, Cardona M, Middle J, Kukreja N, Gati S, Kirk P, Lynch M, Srinivasan M, Szygula J, Baker P, Cruz C, Derigay J, Cigalini C, Lamb K, Nembhard S, Price A, Mamas M, Massey I, Wain J, Delaney J, Junejo S, Martin K, Obaid D, Hoyle V, Brinkworth E, Davies C, Evans D, Richards S, Thomas C, Williams M, Dayer M, Mills H, Roberts K, Goodchild F, Dámaso ES, Greig N, Kundu S, Donaldson D, Tonks L, Beekes M, Button H, Hurford F, Motherwell N, Summers-Wall J, Felmeden D, Tapia V, Keeling P, Sheikh U, Yonis A, Felmeden L, Hughes D, Micklewright L, Summerhayes A, Sutton J, Panoulas V, Prendergast C, Poghosyan K, Rogers P, Barker LN, Batin P, Conway D, Exley D, Fletcher A, Wright J, Nageh T, Hadebe B, Kunhunny S, Mkhitaryan S, Mshengu E, Karthikeyan VJ, Hamdan H, Cooper J, Dandy C, Parkinson V, Paterson P, Reddington S, Taylor T, Tierney C, Adamyan M, Jones KV, Broadley A, Beesley K, Buckley C, Hellyer C, Pippard L, Pitt-Kerby T, Azam J, Hayes C, Freshwater K, Boyadjian S, Johnson L, Mcgill Y, Redfearn H, Russell M, Alyavi A, Alyavi B, Uzokov J, Hayrapetyan H, Azaryan K, Tadevosyan M, Poghosyan H, Kzhdryan H, Vardanyan A, Huber K, Geppert A, Ahmed A, Weidinger F, Derntl M, Hasun M, Schuh-Eiring T, Riegler L, Haq MM, Cader FA, Dewan MAM, Fatema ME, Hasan AS, Islam MM, Khandoker F, Mayedah R, Nizam SU, Azam MG, Arefin MM, Jahan J, Schelfaut D, De Raedt H, Wouters S, Aerts S, Batjoens H, Beauloye C, Dechamps M, Pierard S, Van Caenegem O, Sinnaeve F, Claeys MJ, Snepvangers M, Somers V, Gevaert S, Schaubroek H, Vervaet P, Buysse M, Renders F, Dumoulein M, Hiltrop N, De Coninck M, Naessens S, Senesael I, Hoffer E, Pourbaix S, Beckers J, Dugauquier C, Jacquet S, Malmendier D, Massoz M, Evrard P, Collard L, Brunner P, Carlier S, Blockmans M, Mayne D, Timiras E, Guédès A, Demeure F, Hanet C, Domange J, Jourdan K, Begic E, Custovic F, Dozic A, Hrvat E, Kurbasic I, Mackic D, Subo A, Durak-Nalbantic A, Dzubur A, Rebic D, Hamzic-Mehmedbasic A, Redzepovic A, Djokic-Vejzovic A, Hodzic E, Hujdur M, Musija E, Gljiva-Gogic Z, Serdarevic N, Bajramovic NS, Brigic L, Halilcevic M, Cibo M, Hadžibegic N, Kukavica N, Begic A, Iglica A, Osmanagic A, Resic N, Grgurevic MV, Zvizdic F, Pojskic B, Mujaric E, Selimovic H, Ejubovic M, Pojskic L, Stimjanin E, Sut M, Zapata PS, Munoz CG, Andrade LAF, Upegui MPT, Perez LE, Chavarria J, Quesada D, Alvarado K, Zaputovic L, Tomulic V, Gobic D, Jakljevic T, Lulic D, Bacic G, Bastiancic L, Avraamides P, Eftychiou C, Eteocleous N, Ioannou A, Lambrianidi C, Drakomathioulakis M, Groch L, Hlinomaz O, Rezek M, Semenka J, Sitar J, Beranova M, Kramarikova P, Pesl L, Sindelarova S, Tousek F, Warda HM, Ghaly I, Habiba S, Habib A, Gergis MN, Bahaa H, Samir A, Taha HSE, Adel M, Algamal HM, Mamdouh M, Shaker AF, Shokry K, Konsoah A, Mostafa AM, Ibrahim A, Imam A, Hafez B, Zahran A, Abdelhamid M, Mahmoud K, Mostafa A, Samir A, Abdrabou M, Kamal A, Sallam S, Ali A, Maghraby K, Atta AR, Saad A, Ali M, Lotman EM, Lubi R, Kaljumäe H, Uuetoa T, Kiitam U, Durier C, Ressencourt O, El Din AA, Guiatni A, Bras ML, Mougenot E, Labeque JN, Banos JL, Capendeguy O, Mansourati J, Fofana A, Augagneur M, Bahon L, Pape AL, Batias-Moreau L, Fluttaz A, Good F, Prieur F, Boiffard E, Derien AS, Drapeau I, Roy N, Perret T, Dubreuil O, Ranc S, Rio S, Bonnet JL, Bonnet G, Cuisset T, Deharo P, Mouret JP, Spychaj JC, Blondelon A, Delarche N, Decalf V, Guillard N, Hakme A, Roger MP, Biron Y, Druelles P, Loubeyre C, Lucon A, Hery P, Nejjari M, Digne F, Huchet F, Neykova A, Tzvetkov B, Larrieu M, Quaino G, Armangau P, Sauguet A, Bonfils L, Dumonteil N, Fajadet J, Farah B, Honton B, Monteil B, Philippart R, Tchetche D, Cottin M, Petit F, Piquart A, Popovic B, Varlot J, Maisuradze D, Sagirashvili E, Kereselidze Z, Totladze L, Ginturi T, Lagvilava D, Hamm C, Liebetrau C, Haas M, Hamm C, Koerschgen T, Weferling M, Wolter JS, Maier K, Nickenig G, Sedaghat A, Zachoval C, Lampropoulos K, Mpatsouli A, Sakellaropoulou A, Tyrovolas K, Zibounoumi N, Argyropoulos K, Toulgaridis F, Kolyviras A, Tzanis G, Tzifos V, Milkas A, Papaioannou S, Kyriazopoulos K, Pylarinou V, Kontonassakis I, Kotakos C, Kourgiannidis G, Ntoliou P, Parzakonis N, Pipertzi A, Sakalidis A, Ververeli CL, Kafkala K, Sinanis T, Diakakis G, Grammatikopoulos K, Papoutsaki E, Patialiatos T, Mamaloukaki M, Papadaki ST, Kanellos IE, Antoniou A, Tsinopoulos G, Goudis C, Giannadaki M, Daios S, Petridou M, Skantzis P, Koukis P, Dimitriadis F, Savvidis M, Styliadis I, Sachpekidis V, Pilalidou A, Stamatiadis N, Fotoglidis A, Karakanas A, Ruzsa Z, Becker D, Nowotta F, Gudmundsdottir I, Libungan B, Skuladottir FB, Halldorsdottir H, Shetty R, Iyengar S, Bs C, G S, Lakshmana S, S R, Tripathy N, Sinha A, Choudhary B, Kumar A, Kumar A, Raj R, Roy RS, Dharma S, Siswanto BB, Farhan HA, Yaseen IF, Al-Zaidi M, Dakhil Z, Amen S, Rasool B, Rajeeb A, Amber K, Ali HH, Al-Kinani T, Almyahi MH, Al-Obaidi F, Masoumi G, Sadeghi M, Heshmat-Ghahdarijani K, Roohafza H, Sarrafzadegan N, Shafeie M, Teimouri-Jervekani Z, Noori F, Kyavar M, Sadeghipour P, Firouzi A, Alemzadeh-Ansari MJ, Ghadrdoost B, Golpira R, Ghorbani A, Ahangari F, Salarifar M, Jenab Y, Biria A, Haghighi S, Mansouri P, Yadangi S, Kornowski R, Orvin K, Eisen A, Oginetz N, Vizel R, Kfir H, Pasquale GD, Casella G, Cardelli LS, Filippini E, Zagnoni S, Donazzan L, Ermacora D, Indolfi C, Polimeni A, Curcio A, Mongiardo A, De Rosa S, Sorrentino S, Spaccarotella C, Landolina M, Marino M, Cacucci M, Vailati L, Bernabò P, Montisci R, Meloni L, Marchetti MF, Biddau M, Garau E, Barbato E, Morisco C, Strisciuglio T, Canciello G, Lorenzoni G, Casu G, Merella P, Novo G, D'Agostino A, Di Lisi D, Di Palermo A, Evola S, Immordino F, Rossetto L, Spica G, Pavan D, Mattia AD, Belfiore R, Grandis U, Vendrametto F, Spagnolo C, Carniel L, Sonego E, Gaudio C, Barillà F, Biccire FG, Bruno N, Ferrari I, Paravati V, Torromeo C, Galasso G, Peluso A, Prota C, Radano I, Benvenga RM, Ferraioli D, Anselmi M, Frigo GM, Sinagra G, Merlo M, Perkan A, Ramani F, Altinier A, Fabris E, Rinaldi M, Usmiani T, Checco L, Frea S, Mussida M, Matsukawa R, Sugi K, Kitai T, Furukawa Y, Masumoto A, Miyoshi Y, Nishino S, Assembekov B, Amirov B, Chernokurova Y, Ibragimova F, Mirrakhimov E, Ibraimova A, Murataliev T, Radzhapova Z, Uulu ES, Zhanyshbekova N, Zventsova V, Erglis A, Bondare L, Zaliunas R, Gustiene O, Dirsiene R, Marcinkeviciene J, Sakalyte G, Virbickiene A, Baksyte G, Bardauskiene L, Gelmaniene R, Salkauskaite A, Ziubryte G, Kupstyte-Kristapone N, Badariene J, Balciute S, Kapleriene L, Lizaitis M, Marinskiene J, Navickaite A, Pilkiene A, Ramanauskaite D, Serpytis R, Silinskiene D, Simbelyte T, Staigyte J, Philippe F, Degrell P, Camus E, Ahmad WAW, Kassim ZA, Xuereb RG, Buttigieg LL, Camilleri W, Pllaha E, Xuereb S, Popovici M, Ivanov V, Plugaru A, Moscalu V, Popovici I, Abras M, Ciobanu L, Litvinenco N, Fuior S, Dumanschi C, Ivanov M, Danila T, Grib L, Filimon S, Cardaniuc L, Batrinac A, Tasnic M, Cozma C, Revenco V, Sorici G, Dagva M, Choijiljav G, Dandar E, Khurelbaatar MU, Tsognemekh B, Appelman Y, Den Hartog A, Kolste HJT, Van Den Buijs D, Van'T Hof A, Pustjens T, Houben V, Kasperski I, Ten Berg J, Azzahhafi J, Bor W, Yin DCP, Mbakwem A, Amadi C, Kushimo O, Kilasho M, Oronsaye E, Bakracheski N, Bashuroska EK, Mojsovska V, Tupare S, Dejan M, Jovanoska J, Razmoski D, Marinoski T, Antovski A, Jovanovski Z, Kocho S, Markovski R, Ristovski V, Samir AB, Biserka S, Kalpak O, Peovska IM, Taleska BZ, Pejkov H, Busljetik O, Zimbakov Z, Grueva E, Bojovski I, Tutic M, Poposka L, Vavlukis M, Al-Riyami A, Nadar SK, Abdelmottaleb W, Ahmed S, Mujtaba MS, Al-Mashari S, Al-Riyami H, Laghari AH, Faheem O, Ahmed SW, Qamar N, Furnaz S, Kazmi K, Saghir T, Aneel A, Asim A, Madiha F, Sobkowicz B, Tycinska A, Kazimierczyk E, Szyszkowska A, Mizia-Stec K, Wybraniec M, Bednarek A, Glowacki K, Prokopczuk J, Babinski W, Blachut A, Kosiak M, Kusinska A, Samborski S, Stachura J, Szastok H, Wester A, Bartoszewska D, Sosnowska-Pasiarska B, Krzysiek M, Legutko J, Nawrotek B, Kasprzak JD, Klosinska M, Wiklo K, Kurpesa M, Rechcinski T, Cieslik-Guerra U, Gierlotka M, Bugajski J, Feusette P, Sacha J, Przybylo P, Krzesinski P, Ryczek R, Karasek A, Kazmierczak-Dziuk A, Mielniczuk M, Betkier-Lipinska K, Roik M, Labyk A, Krakowian M, Machowski M, Paczynska M, Potepa M, Pruszczyk P, Budaj A, Ambroziak M, Omelanczuk-Wiech E, Torun A, Opolski G, Glowczynska R, Fojt A, Kowalik R, Huczek Z, Jedrzejczyk S, Roleder T, Brust K, Gasior M, Desperak P, Hawranek M, Farto-Abreu P, Santos M, Baptista S, Brizida L, Faria D, Loureiro J, Magno P, Monteiro C, Nédio M, Tavares J, Sousa C, Almeida I, Almeida S, Miranda H, Santos H, Santos AP, Goncalves L, Monteiro S, Baptista R, Ferreira C, Ferreira J, Goncalves F, Lourenço C, Monteiro P, Picarra B, Santos AR, Guerreiro RA, Carias M, Carrington M, Pais J, de Figueiredo MP, Rocha AR, Mimoso J, De Jesus I, Fernandes R, Guedes J, Mota T, Mendes M, Ferreira J, Tralhão A, Aguiar CT, Strong C, Da Gama FF, Pais G, Timóteo AT, Rosa SAO, Mano T, Reis J, Selas M, Mendes DE, Satendra M, Pinto P, Queirós C, Oliveira I, Reis L, Cruz I, Fernandes R, Torres S, Luz A, Campinas A, Costa R, Frias A, Oliveira M, Martins V, Castilho B, Coelho C, Moura AR, Cotrim N, Dos Santos RC, Custodio P, Duarte R, Gomes R, Matias F, Mendonca C, Neiva J, Rabacal C, Almeida AR, Caeiro D, Queiroz P, Silva G, Pop-Moldovan AL, Darabantiu D, Mercea S, Dan GA, Dan AR, Dobranici M, Popescu RA, Adam C, Sinescu CJ, Andrei CL, Brezeanu R, Samoila N, Baluta MM, Pop D, Tomoaia R, Istratoaie O, Donoiu I, Cojocaru A, Oprita OC, Rocsoreanu A, Grecu M, Ailoaei S, Popescu MI, Cozma A, Babes EE, Rus M, Ardelean A, Larisa R, Moisi M, Ban E, Buzle A, Filimon G, Dobreanu D, Lupu S, Mitre A, Rudzik R, Sus I, Opris D, Somkereki C, Mornos C, Petrescu L, Betiu A, Volcescu A, Ioan O, Luca C, Maximov D, Mosteoru S, Pascalau L, Roman C, Brie D, Crisan S, Erimescu C, Falnita L, Gaita D, Gheorghiu M, Levashov S, Redkina M, Novitskii N, Dementiev E, Baglikov A, Zateyshchikov D, Zubova E, Rogozhina A, Salikov A, Nikitin I, Reznik EV, Komissarova MS, Shebzukhova M, Shitaya K, Stolbova S, Larina V, Akhmatova F, Chuvarayan G, Arefyev MN, Averkov OV, Volkova AL, Sepkhanyan MS, Vecherko VI, Meray I, Babaeva L, Goreva L, Pisaryuk A, Potapov P, Teterina M, Ageev F, Silvestrova G, Fedulaev Y, Pinchuk T, Staroverov I, Kalimullin D, Sukhinina T, Zhukova N, Ryabov V, Kruchinkina E, Vorobeva D, Shevchenko I, Budyak V, Elistratova O, Fetisova E, Islamov R, Ponomareva E, Khalaf H, Shaimaa AA, Kamal W, Alrahimi J, Elshiekh A, Balghith M, Ahmed A, Attia N, Jamiel AA, Potpara T, Marinkovic M, Mihajlovic M, Mujovic N, Kocijancic A, Mijatovic Z, Radovanovic M, Matic D, Milosevic A, Savic L, Subotic I, Uscumlic A, Zlatic N, Antonijevic J, Vesic O, Vucic R, Martinovic SS, Kostic T, Atanaskovic V, Mitic V, Stanojevic D, Petrovic M. Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry. Eur Heart J Qual Care Clin Outcomes 2022; 9:8-15. [PMID: 36259751 DOI: 10.1093/ehjqcco/qcac067] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Accepted: 10/11/2022] [Indexed: 11/12/2022]
Abstract
AIMS The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation. METHODS AND RESULTS Consecutively hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 and 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre. The registry collected data relating to baseline characteristics, major outcomes (in-hospital death, acute heart failure, cardiogenic shock, bleeding, stroke/transient ischaemic attack, and 30-day mortality) and guideline-recommended NSTEMI care interventions: electrocardiogram pre- or in-hospital, pre-hospitalization receipt of aspirin, echocardiography, coronary angiography, referral to cardiac rehabilitation, smoking cessation advice, dietary advice, and prescription on discharge of aspirin, P2Y12 inhibition, angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor blocker (ARB), beta-blocker, and statin. CONCLUSION The EORP NSTEMI Registry is an international, prospective registry of care and outcomes of patients treated for NSTEMI, which will provide unique insights into the contemporary management of hospitalised NSTEMI patients, compliance with ESC 2015 NSTEMI Guidelines, and identify potential barriers to optimal management of this common clinical presentation associated with significant morbidity and mortality.
Collapse
Affiliation(s)
- Ramesh Nadarajah
- Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK.,Leeds Institute of Data Analytics, University of Leeds, LS2 9JT Leeds, UK.,Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK
| | - Peter Ludman
- Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK
| | - Yolande Appelman
- Department of Cardiology, Amsterdam UMC-Vrije Universiteit, Amsterdam Cardiovascular Sciences, Amsterdam, Netherlands
| | - Salvatore Brugaletta
- Hospital Clinic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
| | - Andrzej Budaj
- Department of Cardiology, Center of Postgraduate Medical Education, Grochowski Hospital, Warsaw, Poland
| | - Hector Bueno
- Cardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.,Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain.,Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
| | - Kurt Huber
- 3rd Medical Department, Cardiology and Intensive Care Medicine, Clinic Ottakring (Wilhelminenhospital), Vienna, Austria.,Medical Faculty, Sigmund Freud University, Vienna, Austria
| | - Vijay Kunadian
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.,Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
| | - Sergio Leonardi
- University of Pavia, Pavia, Italy.,Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy
| | - Maddalena Lettino
- Cardio-Thoracic and Vascular Department, San Gerardo Hospital, ASST-Monza, Monza, Italy
| | - Dejan Milasinovic
- Department of Cardiology, University Clinical Center of Serbia and Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - Chris P Gale
- Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, UK.,Leeds Institute of Data Analytics, University of Leeds, LS2 9JT Leeds, UK.,Department of Cardiology, Leeds Teaching Hospitals NHS Trust, LS1 3EX Leeds, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Swan D, Henderson R, McEllistrim C, Naicker SD, Quinn J, Cahill MR, Mykytiv V, Lenihan E, Mulvaney E, Nolan M, Parker I, Natoni A, Lynch K, Ryan AE, Szegezdi E, Krawczyk J, Murphy P, O'Dwyer M. CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. Clin Lymphoma Myeloma Leuk 2022; 22:847-852. [PMID: 35985959 DOI: 10.1016/j.clml.2022.07.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 06/25/2022] [Accepted: 07/18/2022] [Indexed: 06/15/2023]
Abstract
The phase 1b 16-BCNI-001/CTRIAL-IE 16-02 CyBorD-DARA trial investigated the combination of Daratumumab with cyclophosphamide, bortezomib and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM), followed by autologous stem cell transplantation and Daratumumab maintenance. CR/sCR rates were 50% after transplant and 62.5% at end of treatment. The overall percentage of patients achieving complete response or better was 77.8%. Progression-free survival rate at end of maintenance was 81.3% and estimated 2-year overall survival was 88.9%. 37.5% of patients demonstrated sustained MRD negativity to a level of 10-5 from transplant to analysis at EOT. In this phase 1b study, we have shown CyBorD-DARA to be an effective and well-tolerated immunomodulatory agent-free regiment in transplant-eligible NDMM.
Collapse
Affiliation(s)
- D Swan
- Department of Hematology, University Hospital Galway, Galway, Ireland.
| | - R Henderson
- Department of Hematology, University Hospital Galway, Galway, Ireland
| | - C McEllistrim
- Department of Hematology, University Hospital Galway, Galway, Ireland
| | - S D Naicker
- School of Medicine, College of Medicine, Nursing and Health Sciences, NUI Galway, Galway, Ireland; Discipline of Pharmacology & Therapeutics, School of Medicine, College of Medicine, Nursing, and Health Sciences, National University of Ireland Galway, Galway, Ireland
| | - J Quinn
- Blood Cancer Network Ireland, Ireland; Department of Haematology, Beaumont Hospital, Dublin, Ireland
| | - M R Cahill
- Blood Cancer Network Ireland, Ireland; Cancer Research at UCC, University College Cork, Cork, Ireland; Cancer Trials Ireland, Dublin, Ireland
| | - V Mykytiv
- Department of Hematology, Cork University Hospital, Cork, Ireland; Cancer Trials Ireland, Dublin, Ireland
| | - E Lenihan
- Department of Hematology, Cork University Hospital, Cork, Ireland
| | | | - M Nolan
- Cancer Trials Ireland, Dublin, Ireland
| | - I Parker
- Cancer Trials Ireland, Dublin, Ireland
| | - A Natoni
- School of Medicine, College of Medicine, Nursing and Health Sciences, NUI Galway, Galway, Ireland; Haematology, Department of Translational and Precision Medicine, Sapienza University
| | - K Lynch
- School of Medicine, College of Medicine, Nursing and Health Sciences, NUI Galway, Galway, Ireland; Discipline of Pharmacology & Therapeutics, School of Medicine, College of Medicine, Nursing, and Health Sciences, National University of Ireland Galway, Galway, Ireland
| | - A E Ryan
- Discipline of Pharmacology & Therapeutics, School of Medicine, College of Medicine, Nursing, and Health Sciences, National University of Ireland Galway, Galway, Ireland; Lambe Institute for Translation research, School of Medicine, College of Medicine, Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland
| | | | - J Krawczyk
- Department of Hematology, University Hospital Galway, Galway, Ireland; Blood Cancer Network Ireland, Ireland; Cancer Trials Ireland, Dublin, Ireland
| | - P Murphy
- Blood Cancer Network Ireland, Ireland; Department of Haematology, Beaumont Hospital, Dublin, Ireland; Cancer Trials Ireland, Dublin, Ireland
| | - M O'Dwyer
- Department of Hematology, University Hospital Galway, Galway, Ireland; Blood Cancer Network Ireland, Ireland
| |
Collapse
|
8
|
Safarpour D, Brumbach BH, Arena M, Quinn J, Diamond S, Nutt JG, Pfeiffer R. Gastrointestinal Motility and Response to Levodopa in Parkinson's Disease: A Proof-of-Concept Study. Mov Disord 2022; 37:2153-2158. [PMID: 35969014 DOI: 10.1002/mds.29176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 06/24/2022] [Accepted: 07/18/2022] [Indexed: 11/06/2022] Open
Abstract
BACKGROUND Simultaneous measurement of gastrointestinal transit time (GITT) and plasma levodopa concentration (PLC) is crucial to understanding the effect of dysfunctional motility on levodopa response in patients with Parkinson's disease (PwPD). OBJECTIVE The aim is to determine if altered segmental GITT correlates with clinical response and PLC variability in PwPD. METHODS Ten typical and 10 erratic responders ingested the SmartPill (SP) wireless motility capsule. Serial PLC and finger tapping, obtained every 30 minutes for 3 hours after SP/levodopa ingestion, evaluated the correlation between GITT, clinical response, and PLC. Glucose breath testing assessed small intestinal bacterial overgrowth (SIBO). RESULTS GITT was not significantly different in "typical" and "erratic" responders. SIBO was positive in half of the erratic and negative in most typical responders. CONCLUSION SP is a feasible technology for assessing GITT in PwPD. A larger study may be able to significantly differentiate/correlate GITT in different segments of the GI tract with response to levodopa. © 2022 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Delaram Safarpour
- Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA
| | - Barbara H Brumbach
- OHSU-PSU School of Public Health, Biostatistics and Design Program, Oregon Health & Science University, Portland, Oregon, USA
| | - Monica Arena
- Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA
| | - Joseph Quinn
- Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA
| | - Sarah Diamond
- Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA
| | - Jay G Nutt
- Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA
| | - RonaldF Pfeiffer
- Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA
| |
Collapse
|
9
|
Cahill K, Giandrea M, Quinn J, Sacco L, Platts L. Does Bridge Employment Mitigate or Exacerbate Inequalities Later in Life? Innov Aging 2021. [PMCID: PMC8969930 DOI: 10.1093/geroni/igab046.1603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
This paper explores how gradual retirement impacts inequality later in life, with a focus on transitions from career to bridge employment. We use 26 years of longitudinal data from the Health and Retirement Study to document the various pathways that older Americans take when exiting the labor force, and examine how bridge employment impacts non-housing wealth and total wealth, including the present discounted value of Social Security benefits. We find that gradual retirement in the form of bridge employment neither exacerbates nor mitigates wealth inequalities among Americans who held career jobs later in life. We do find evidence that wealth inequalities grow among the subset of older career workers who transition from career employment to bridge employer at older ages. These findings provide quantitative evidence that bridge employment at older ages is taken by those who need to continue working financially and those who continue working for nonpecuniary reasons.
Collapse
Affiliation(s)
- Kevin Cahill
- Center on Aging & Work at Boston College, Chestnut Hill, Massachusetts, United States
| | - Michael Giandrea
- U.S. Bureau of Labor Statistics, Washington, District of Columbia, United States
| | - Joseph Quinn
- Boston College, Chestnut Hill, Massachusetts, United States
| | | | - Loretta Platts
- Stress Research Institute, Department of Psychology, Stockholm University, Stockholm, Stockholms Lan, Sweden
| |
Collapse
|
10
|
Vitorio R, Stuart S, Giritharan A, Quinn J, Nutt JG, Mancini M. Changes in prefrontal cortical activity and turning in response to dopaminergic and cholinergic therapy in Parkinson's disease: A randomized cross-over trial. Parkinsonism Relat Disord 2021; 86:10-14. [PMID: 33813359 DOI: 10.1016/j.parkreldis.2021.03.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Revised: 12/10/2020] [Accepted: 03/15/2021] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Cholinergic dysfunction contributes to mobility deficits in Parkinson's disease (PD). People with PD rely on limited prefrontal executive-attentional resources for the control of locomotion, including turning. Cortical and behavioral responses to cholinergic augmentation during turning remains unclear. We examined prefrontal cortex (PFC) activity while turning-in-place and spatiotemporal measures of turns in response to usual dopaminergic medication and adjunct cholinergic augmentation. METHODS This study consisted of a single-site, randomized, double-blind crossover trial. Twenty PD participants were assessed in the levodopa-off state and then randomized to either levodopa + donepezil (5 mg) or levodopa + placebo treatments for two weeks followed by a 2-week washout before crossover. The primary outcome was change from off state in PFC activity while turning-in-place (assessed with functional near-infrared spectroscopy). Secondary outcomes were changes in spatiotemporal turning measures (assessed with body-worn inertial measurement units) and accuracy in the secondary task. RESULTS Nineteen participants completed the trial. While levodopa + placebo had no effect on PFC activity when turning-in-place with a dual-task, levodopa + donepezil led to a large reduction in PFC activity (effect size, -0.82). Spatiotemporal measures of turning improved with both treatments, with slightly greater effect sizes observed for levodopa + donepezil. Additionally, the accuracy in the concurrent cognitive task improved only with levodopa + donepezil (effect size, 0.63). CONCLUSION The addition of cholinergic therapy with donepezil (5 mg/day for 2 weeks) to standard dopaminergic therapy reduced the burden on prefrontal executive-attentional resources while turning with a dual-task and improved secondary task accuracy and turning.
Collapse
Affiliation(s)
- Rodrigo Vitorio
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Samuel Stuart
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States; Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle Upon Tyne, UK
| | - Andrew Giritharan
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Joseph Quinn
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - John G Nutt
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States
| | - Martina Mancini
- Department of Neurology, Oregon Health & Science University, Portland, OR, United States.
| |
Collapse
|
11
|
Ryzhikova E, Ralbovsky NM, Sikirzhytski V, Kazakov O, Halamkova L, Quinn J, Zimmerman EA, Lednev IK. Raman spectroscopy and machine learning for biomedical applications: Alzheimer's disease diagnosis based on the analysis of cerebrospinal fluid. Spectrochim Acta A Mol Biomol Spectrosc 2021; 248:119188. [PMID: 33268033 DOI: 10.1016/j.saa.2020.119188] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Revised: 10/29/2020] [Accepted: 11/01/2020] [Indexed: 06/12/2023]
Abstract
Current Alzheimer's disease (AD) diagnostics is based on clinical assessments, imaging and neuropsychological tests that are efficient only at advanced stages of the disease. Early diagnosis of AD will provide decisive opportunities for preventive treatment and development of disease-modifying drugs. Cerebrospinal fluid (CSF) is in direct contact with the human brain, where the deadly pathological process of the disease occurs. As such, the CSF biochemical composition reflects specific changes associated with the disease and is therefore the most promising body fluid for AD diagnostic test development. Here, we describe a new method to diagnose AD based on CSF via near infrared (NIR) Raman spectroscopy in combination with machine learning analysis. Raman spectroscopy is capable of probing the entire biochemical composition of a biological fluid at once. It has great potential to detect small changes specific to AD, even at the earliest stages of pathogenesis. NIR Raman spectra were measured of CSF samples acquired from 21 patients diagnosed with AD and 16 healthy control (HC) subjects. Artificial neural networks (ANN) and support vector machine discriminant analysis (SVM-DA) statistical methods were used for differentiation purposes, with the most successful results allowing for the differentiation of AD and HC subjects with 84% sensitivity and specificity. Our classification models show high discriminative power, suggesting the method has a great potential for AD diagnostics. The reported Raman spectroscopic examination of CSF can complement current clinical tests, making early AD detection fast, accurate, and inexpensive. While this study shows promise using a small sample set, further method validation on a larger scale is required to indicate the true strength of the approach.
Collapse
Affiliation(s)
- Elena Ryzhikova
- Department of Chemistry, University at Albany, SUNY, 1400 Washington Avenue, Albany, NY 12222, USA
| | - Nicole M Ralbovsky
- Department of Chemistry, University at Albany, SUNY, 1400 Washington Avenue, Albany, NY 12222, USA
| | - Vitali Sikirzhytski
- Department of Chemistry, University at Albany, SUNY, 1400 Washington Avenue, Albany, NY 12222, USA
| | - Oleksandr Kazakov
- Department of Physics, University at Albany, SUNY, 1400 Washington Avenue, Albany, NY 12222, USA
| | - Lenka Halamkova
- Department of Chemistry, University at Albany, SUNY, 1400 Washington Avenue, Albany, NY 12222, USA
| | - Joseph Quinn
- Layton Aging and Alzheimer's Center, Oregon Health & Science University, Portland, OR 97239, USA
| | - Earl A Zimmerman
- Alzheimer's Center, Department of Neurology of Albany Medical Center, Albany, NY 12222, USA
| | - Igor K Lednev
- Department of Chemistry, University at Albany, SUNY, 1400 Washington Avenue, Albany, NY 12222, USA.
| |
Collapse
|
12
|
Höglinger GU, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B, Lon HK, Jin Z, Fisseha N, Budur K, Gold M, Ryman D, Florian H, Ahmed A, Aiba I, Albanese A, Bertram K, Bordelon Y, Bower J, Brosch J, Claassen D, Colosimo C, Corvol JC, Cudia P, Daniele A, Defebvre L, Driver-Dunckley E, Duquette A, Eleopra R, Eusebio A, Fung V, Geldmacher D, Golbe L, Grandas F, Hall D, Hatano T, Höglinger GU, Honig L, Hui J, Kerwin D, Kikuchi A, Kimber T, Kimura T, Kumar R, Litvan I, Ljubenkov P, Lorenzl S, Ludolph A, Mari Z, McFarland N, Meissner W, Mir Rivera P, Mochizuki H, Morgan J, Munhoz R, Nishikawa N, O`Sullivan J, Oeda T, Oizumi H, Onodera O, Ory-Magne F, Peckham E, Postuma R, Quattrone A, Quinn J, Ruggieri S, Sarna J, Schulz PE, Slevin J, Tagliati M, Wile D, Wszolek Z, Xie T, Zesiewicz T. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol 2021; 20:182-192. [DOI: 10.1016/s1474-4422(20)30489-0] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 10/07/2020] [Accepted: 12/11/2020] [Indexed: 12/13/2022]
|
13
|
Marrinan A, Shackleton L, Kelly C, Lavin M, Glavey S, Murphy P, Quinn J. Liver injury during rivaroxaban treatment in a patient with AL amyloidosis. Eur J Clin Pharmacol 2021; 77:1073-1076. [PMID: 33427957 DOI: 10.1007/s00228-020-03084-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2020] [Accepted: 12/28/2020] [Indexed: 11/25/2022]
Affiliation(s)
- Alan Marrinan
- Department of Haematology, Beaumont Hospital, Dublin 9, Ireland.
| | - L Shackleton
- Department of Haematology, Beaumont Hospital, Dublin 9, Ireland
| | - C Kelly
- Department of Haematology, Beaumont Hospital, Dublin 9, Ireland
| | - M Lavin
- Department of Haematology, Beaumont Hospital, Dublin 9, Ireland.,Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland (RCSI), Dublin 2, Ireland
| | - S Glavey
- Department of Haematology, Beaumont Hospital, Dublin 9, Ireland.,Department of Medicine, RCSI, Dublin, Ireland
| | - P Murphy
- Department of Haematology, Beaumont Hospital, Dublin 9, Ireland.,Department of Medicine, RCSI, Dublin, Ireland
| | - J Quinn
- Department of Haematology, Beaumont Hospital, Dublin 9, Ireland.,Department of Medicine, RCSI, Dublin, Ireland
| |
Collapse
|
14
|
Gordin E, Gordin D, Viitanen S, Szlosek D, Coyne M, Farace G, Murphy R, Quinn J, Yerramilli M, Yerramilli M, Spillmann T. Urinary clusterin and cystatin B as biomarkers of tubular injury in dogs following envenomation by the European adder. Res Vet Sci 2020; 134:12-18. [PMID: 33278755 DOI: 10.1016/j.rvsc.2020.11.019] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 10/14/2020] [Accepted: 11/22/2020] [Indexed: 12/20/2022]
Abstract
Diagnosing acute kidney injury remains a challenge since the established renal biomarkers, serum creatinine (sCr) and symmetric dimethylarginine (SDMA) reflect glomerular function and not tubular injury. Sensitive tubular markers such as urinary clusterin (uClust) and cystatin B (uCysB) have been proposed to detect AKI at an earlier stage. Since envenomation by the European adder (Vipera berus berus) could serve as a spontaneous disease model of AKI we investigated these new biomarkers in affected dogs. Concentrations of uClust and uCysB as well as sCr and SDMA were analyzed retrospectively in stored samples from 26 dogs with snake envenomation and 13 healthy controls. Higher concentrations of uClust (P < 0.012) and uCysB (P < 0.001) were observed in the snake-envenomed group. Normalization of uClust and uCysB to urinary creatinine did not alter the results. No differences were observed in sCr and SDMA between the snake-envenomed group and the healthy control group. Spearman rank correlation analysis revealed a strong association of uClust with uCysB in the snake-envenomed dogs (r = 0.75 P < 0.001) but not in the healthy controls. The high percentage of snake-envenomed dogs with increased uClust and uCysB concentrations in the absence of increased sCr and SDMA suggests renal tubular injury in the affected dogs. Larger prospective case-controlled studies are warranted to evaluate the clinical utility and prognostic value of these biomarkers.
Collapse
Affiliation(s)
- E Gordin
- Faculty of Veterinary Medicine, Department of Equine and Small Animal Medicine, Internal Medicine Section, University of Helsinki, P.O. Box 57, 00014 University of Helsinki, Finland.
| | - D Gordin
- Abdominal Center Nephrology, Helsinki University Hospital, Folkhälsan Research Center, University of Helsinki, Helsinki, Finland
| | - S Viitanen
- Faculty of Veterinary Medicine, Department of Equine and Small Animal Medicine, Internal Medicine Section, University of Helsinki, P.O. Box 57, 00014 University of Helsinki, Finland
| | - D Szlosek
- IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, ME 04092, United States
| | - M Coyne
- IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, ME 04092, United States
| | - G Farace
- IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, ME 04092, United States
| | - R Murphy
- IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, ME 04092, United States
| | - J Quinn
- IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, ME 04092, United States
| | - Ma Yerramilli
- IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, ME 04092, United States
| | - Mu Yerramilli
- IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, ME 04092, United States
| | - T Spillmann
- Faculty of Veterinary Medicine, Department of Equine and Small Animal Medicine, Internal Medicine Section, University of Helsinki, P.O. Box 57, 00014 University of Helsinki, Finland
| |
Collapse
|
15
|
Brownstein MJ, Simon NG, Long JD, Yankey J, Maibach HT, Cudkowicz M, Coffey C, Conwit RA, Lungu C, Anderson KE, Hersch SM, Ecklund DJ, Damiano EM, Itzkowitz DE, Lu S, Chase MK, Shefner JM, McGarry A, Thornell B, Gladden C, Costigan M, O’Suilleabhain P, Marshall FJ, Chesire AM, Deritis P, Adams JL, Hedera P, Lowen K, Rosas HD, Hiller AL, Quinn J, Keith K, Duker AP, Gruenwald C, Molloy A, Jacob C, Factor S, Sperin E, Bega D, Brown ZR, Seeberger LC, Sung VW, Benge M, Kostyk SK, Daley AM, Perlman S, Suski V, Conlon P, Barrett MJ, Lowenhaupt S, Quigg M, Perlmutter JS, Wright BA, Most E, Schwartz GJ, Lamb J, Chuang RS, Singer C, Marder K, Moran JA, Singleton JR, Zorn M, Wall PV, Dubinsky RM, Gray C, Drazinic C. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. J Clin Med 2020; 9:E3682. [PMID: 33207828 PMCID: PMC7696926 DOI: 10.3390/jcm9113682] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2020] [Revised: 11/06/2020] [Accepted: 11/09/2020] [Indexed: 11/16/2022] Open
Abstract
SRX246 is a vasopressin (AVP) 1a receptor antagonist that crosses the blood-brain barrier. It reduced impulsive aggression, fear, depression and anxiety in animal models, blocked the actions of intranasal AVP on aggression/fear circuits in an experimental medicine fMRI study and demonstrated excellent safety in Phase 1 multiple-ascending dose clinical trials. The present study was a 3-arm, multicenter, randomized, placebo-controlled, double-blind, 12-week, dose escalation study of SRX246 in early symptomatic Huntington's disease (HD) patients with irritability. Our goal was to determine whether SRX246 was safe and well tolerated in these HD patients given its potential use for the treatment of problematic neuropsychiatric symptoms. Participants were randomized to receive placebo or to escalate to 120 mg twice daily or 160 mg twice daily doses of SRX246. Assessments included standard safety tests, the Unified Huntington's Disease Rating Scale (UHDRS), and exploratory measures of problem behaviors. The groups had comparable demographics, features of HD and baseline irritability. Eighty-two out of 106 subjects randomized completed the trial on their assigned dose of drug. One-sided exact-method confidence interval tests were used to reject the null hypothesis of inferior tolerability or safety for each dose group vs. placebo. Apathy and suicidality were not affected by SRX246. Most adverse events in the active arms were considered unlikely to be related to SRX246. The compound was safe and well tolerated in HD patients and can be moved forward as a candidate to treat irritability and aggression.
Collapse
Affiliation(s)
- Michael J. Brownstein
- Azevan Pharmaceuticals, Inc., Bethlehem, PA 18015, USA; (N.G.S.); (H.T.M.); (E.M.D.); (D.E.I.); (S.L.)
| | - Neal G. Simon
- Azevan Pharmaceuticals, Inc., Bethlehem, PA 18015, USA; (N.G.S.); (H.T.M.); (E.M.D.); (D.E.I.); (S.L.)
- Department of Biological Sciences, Lehigh University, Bethlehem, PA 18015, USA
| | - Jeffrey D. Long
- Department of Biostatistics, University of Iowa, Iowa City, IA 52242, USA; (J.D.L.); (J.Y.); (C.C.); (D.J.E.); (M.C.)
| | - Jon Yankey
- Department of Biostatistics, University of Iowa, Iowa City, IA 52242, USA; (J.D.L.); (J.Y.); (C.C.); (D.J.E.); (M.C.)
| | - Hilda T. Maibach
- Azevan Pharmaceuticals, Inc., Bethlehem, PA 18015, USA; (N.G.S.); (H.T.M.); (E.M.D.); (D.E.I.); (S.L.)
| | - Merit Cudkowicz
- Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA; (M.C.); (S.M.H.); (M.K.C.); (B.T.); (C.G.); (H.D.R.)
| | - Christopher Coffey
- Department of Biostatistics, University of Iowa, Iowa City, IA 52242, USA; (J.D.L.); (J.Y.); (C.C.); (D.J.E.); (M.C.)
| | - Robin A. Conwit
- National Institutes of Health, NINDS, Bethesda, MD 20852, USA; (R.A.C.); (C.L.)
| | - Codrin Lungu
- National Institutes of Health, NINDS, Bethesda, MD 20852, USA; (R.A.C.); (C.L.)
| | - Karen E. Anderson
- Department of Neurology, Medstar Georgetown University Hospital, Washington, DC 20007, USA;
| | - Steven M. Hersch
- Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA; (M.C.); (S.M.H.); (M.K.C.); (B.T.); (C.G.); (H.D.R.)
- Voyager Therapeutics Inc., Cambridge, MA 02139, USA
| | - Dixie J. Ecklund
- Department of Biostatistics, University of Iowa, Iowa City, IA 52242, USA; (J.D.L.); (J.Y.); (C.C.); (D.J.E.); (M.C.)
| | - Eve M. Damiano
- Azevan Pharmaceuticals, Inc., Bethlehem, PA 18015, USA; (N.G.S.); (H.T.M.); (E.M.D.); (D.E.I.); (S.L.)
| | - Debra E. Itzkowitz
- Azevan Pharmaceuticals, Inc., Bethlehem, PA 18015, USA; (N.G.S.); (H.T.M.); (E.M.D.); (D.E.I.); (S.L.)
| | - Shifang Lu
- Azevan Pharmaceuticals, Inc., Bethlehem, PA 18015, USA; (N.G.S.); (H.T.M.); (E.M.D.); (D.E.I.); (S.L.)
- Department of Biological Sciences, Lehigh University, Bethlehem, PA 18015, USA
| | - Marianne K. Chase
- Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA; (M.C.); (S.M.H.); (M.K.C.); (B.T.); (C.G.); (H.D.R.)
| | - Jeremy M. Shefner
- Barrow Neurological Institute, Phoenix, AZ 85013, USA;
- Department of Neurology, College of Medicine, The University of Arizona, Phoenix, AZ 85004, USA
- Department of Neurology, College of Medicine, Creighton University, Phoenix, AZ 85013, USA
| | - Andrew McGarry
- Department of Neurology, Cooper University Hospital, Camden, NJ 08103, USA;
| | - Brenda Thornell
- Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA; (M.C.); (S.M.H.); (M.K.C.); (B.T.); (C.G.); (H.D.R.)
| | - Catherine Gladden
- Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA; (M.C.); (S.M.H.); (M.K.C.); (B.T.); (C.G.); (H.D.R.)
| | - Michele Costigan
- Department of Biostatistics, University of Iowa, Iowa City, IA 52242, USA; (J.D.L.); (J.Y.); (C.C.); (D.J.E.); (M.C.)
| | | | - Frederick J. Marshall
- Department of Neurology, University of Rochester Medical Center, Rochester, NY 14618, USA; (F.J.M.); (A.M.C.); (P.D.); (J.L.A.)
| | - Amy M. Chesire
- Department of Neurology, University of Rochester Medical Center, Rochester, NY 14618, USA; (F.J.M.); (A.M.C.); (P.D.); (J.L.A.)
| | - Paul Deritis
- Department of Neurology, University of Rochester Medical Center, Rochester, NY 14618, USA; (F.J.M.); (A.M.C.); (P.D.); (J.L.A.)
| | - Jamie L. Adams
- Department of Neurology, University of Rochester Medical Center, Rochester, NY 14618, USA; (F.J.M.); (A.M.C.); (P.D.); (J.L.A.)
| | - Peter Hedera
- Department of Neurology, Vanderbilt University, Nashville, TN 37212, USA; (P.H.); (K.L.)
| | - Kelly Lowen
- Department of Neurology, Vanderbilt University, Nashville, TN 37212, USA; (P.H.); (K.L.)
| | - H. Diana Rosas
- Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA; (M.C.); (S.M.H.); (M.K.C.); (B.T.); (C.G.); (H.D.R.)
| | - Amie L. Hiller
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; (A.L.H.); (J.Q.); (K.K.)
| | - Joseph Quinn
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; (A.L.H.); (J.Q.); (K.K.)
| | - Kellie Keith
- Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA; (A.L.H.); (J.Q.); (K.K.)
| | - Andrew P. Duker
- Department of Neurology, University of Cincinnati, Cincinnati, OH 45219, USA; (A.P.D.); (C.G.); (A.M.); (C.J.)
| | - Christina Gruenwald
- Department of Neurology, University of Cincinnati, Cincinnati, OH 45219, USA; (A.P.D.); (C.G.); (A.M.); (C.J.)
| | - Angela Molloy
- Department of Neurology, University of Cincinnati, Cincinnati, OH 45219, USA; (A.P.D.); (C.G.); (A.M.); (C.J.)
| | - Cara Jacob
- Department of Neurology, University of Cincinnati, Cincinnati, OH 45219, USA; (A.P.D.); (C.G.); (A.M.); (C.J.)
| | - Stewart Factor
- Department of Neurology, Emory University, Atlanta, GA 30322, USA; (S.F.); (E.S.)
| | - Elaine Sperin
- Department of Neurology, Emory University, Atlanta, GA 30322, USA; (S.F.); (E.S.)
| | - Danny Bega
- Department of Neurology, Northwestern University, Chicago, IL 60611, USA; (D.B.); (Z.B.)
| | - Zsazsa R. Brown
- Department of Neurology, Northwestern University, Chicago, IL 60611, USA; (D.B.); (Z.B.)
| | - Lauren C. Seeberger
- Department of Neurology, University of Colorado Denver, Aurora, CO 80045, USA;
| | - Victor W. Sung
- Department of Neurology, The University of Alabama at Birmingham, Birmingham, AL 35233, USA; (V.W.S.); (M.B)
| | - Melanie Benge
- Department of Neurology, The University of Alabama at Birmingham, Birmingham, AL 35233, USA; (V.W.S.); (M.B)
| | - Sandra K. Kostyk
- Department of Neurology, Ohio State University, Columbus, OH 43210, USA; (S.K.K.); (A.M.D.)
| | - Allison M. Daley
- Department of Neurology, Ohio State University, Columbus, OH 43210, USA; (S.K.K.); (A.M.D.)
| | - Susan Perlman
- Department of Neurology, University of California Los Angeles, Los Angeles, CA 90095, USA;
| | - Valerie Suski
- Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA; (V.S.); (P.C.)
| | - Patricia Conlon
- Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA; (V.S.); (P.C.)
| | - Matthew J. Barrett
- Department of Neurology, Virginia Commonwealth University, Richmond, VA 23298, USA; (M.J.B.); (S.L.); (M.Q.)
| | - Stephanie Lowenhaupt
- Department of Neurology, Virginia Commonwealth University, Richmond, VA 23298, USA; (M.J.B.); (S.L.); (M.Q.)
| | - Mark Quigg
- Department of Neurology, Virginia Commonwealth University, Richmond, VA 23298, USA; (M.J.B.); (S.L.); (M.Q.)
| | - Joel S. Perlmutter
- Department of Neurology, Washington University, Saint Louis, MO 63110, USA; (J.S.P.); (E.M.)
| | - Brenton A. Wright
- Department of Neurosciences, University of California San Diego, La Jolla, CA 92121, USA;
| | - Elaine Most
- Department of Neurology, Washington University, Saint Louis, MO 63110, USA; (J.S.P.); (E.M.)
| | - Guy J. Schwartz
- Department of Neurology, Stony Brook University Hospital, Stony Brook, NY 11794, USA; (G.J.S.); (J.L.)
| | - Jessica Lamb
- Department of Neurology, Stony Brook University Hospital, Stony Brook, NY 11794, USA; (G.J.S.); (J.L.)
| | - Rosalind S. Chuang
- Department of Neurology, Swedish Medical Center, Seattle, WA 98122, USA;
| | - Carlos Singer
- Department of Neurology, University of Miami, Miami, FL 33136, USA;
| | - Karen Marder
- Department of Neurology, Columbia University, New York, NY 10032, USA; (K.M.); (J.A.M.)
| | - Joyce A. Moran
- Department of Neurology, Columbia University, New York, NY 10032, USA; (K.M.); (J.A.M.)
| | - John R. Singleton
- Clinical Neurosciences Center, University of Utah, Salt Lake City, UT 84132, USA; (J.R.S.); (M.Z.); (P.V.W.)
| | - Meghan Zorn
- Clinical Neurosciences Center, University of Utah, Salt Lake City, UT 84132, USA; (J.R.S.); (M.Z.); (P.V.W.)
| | - Paola V. Wall
- Clinical Neurosciences Center, University of Utah, Salt Lake City, UT 84132, USA; (J.R.S.); (M.Z.); (P.V.W.)
| | - Richard M. Dubinsky
- Department of Neurology, University of Kansas Medical Center, Kansas City, KS 66160, USA; (R.M.D.); (C.G.)
| | - Carolyn Gray
- Department of Neurology, University of Kansas Medical Center, Kansas City, KS 66160, USA; (R.M.D.); (C.G.)
| | - Carolyn Drazinic
- Department of Clinical Sciences, Florida State University, Tallahassee, FL 32306, USA;
| |
Collapse
|
16
|
Alcazar Magana A, Wright K, Vaswani A, Caruso M, Reed RL, Bailey CF, Nguyen T, Gray NE, Soumyanath A, Quinn J, Stevens JF, Maier CS. Integration of mass spectral fingerprinting analysis with precursor ion (MS1) quantification for the characterisation of botanical extracts: application to extracts of Centella asiatica (L.) Urban. Phytochem Anal 2020; 31:722-738. [PMID: 32281154 PMCID: PMC7587007 DOI: 10.1002/pca.2936] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Revised: 03/12/2020] [Accepted: 03/22/2020] [Indexed: 05/16/2023]
Abstract
INTRODUCTION The phytochemical composition of plant material governs the bioactivity and potential health benefits as well as the outcomes and reproducibility of laboratory studies and clinical trials. OBJECTIVE The objective of this work was to develop an efficient method for the in-depth characterisation of plant extracts and quantification of marker compounds that can be potentially used for subsequent product integrity studies. Centella asiatica (L.) Urb., an Ayurvedic herb with potential applications in enhancing mental health and cognitive function, was used as a case study. METHODS A quadrupole time-of-flight analyser in conjunction with an optimised high-performance liquid chromatography (HPLC) separation was used for in-depth untargeted fingerprinting and post-acquisition precursor ion quantification to determine levels of distinct phytochemicals in various C. asiatica extracts. RESULTS We demonstrate the utility of this workflow for the characterisation of extracts of C. asiatica. This integrated workflow allowed the identification or tentative identification of 117 compounds, chemically interconnected based on Tanimoto chemical similarity, and the accurate quantification of 24 phytochemicals commonly found in C. asiatica extracts. CONCLUSION We report a phytochemical analysis method combining liquid chromatography, high resolution mass spectral data acquisition, and post-acquisition interrogation that allows chemical fingerprints of botanicals to be obtained in conjunction with accurate quantification of distinct phytochemicals. The variability in the composition of specialised metabolites across different C. asiatica accessions was substantial, demonstrating that detailed characterisation of plant extracts is a prerequisite for reproducible use in laboratory studies, clinical trials and safe consumption. The methodological approach is generally applicable to other botanical products.
Collapse
Affiliation(s)
- Armando Alcazar Magana
- Department of ChemistryOregon State UniversityCorvallisORUSA
- Linus Pauling InstituteOregon State UniversityCorvallisORUSA
| | - Kirsten Wright
- Department of NeurologyOregon Health and Science UniversityPortlandORUSA
| | - Ashish Vaswani
- Department of ChemistryOregon State UniversityCorvallisORUSA
| | - Maya Caruso
- Department of NeurologyOregon Health and Science UniversityPortlandORUSA
| | - Ralph L. Reed
- Department of Pharmaceutical SciencesOregon State UniversityCorvallisORUSA
- Linus Pauling InstituteOregon State UniversityCorvallisORUSA
| | | | - Thuan Nguyen
- OHSU‐PSU School of Public Health, Oregon Health & Science UniversityPortlandORUSA
| | - Nora E. Gray
- Department of NeurologyOregon Health and Science UniversityPortlandORUSA
| | - Amala Soumyanath
- Department of NeurologyOregon Health and Science UniversityPortlandORUSA
| | - Joseph Quinn
- Department of NeurologyOregon Health and Science UniversityPortlandORUSA
- Department of Neurology and Parkinson's Disease Research Education and Clinical Care Center (PADRECC), VA Portland Healthcare SystemPortlandORUSA
| | - Jan F. Stevens
- Department of Pharmaceutical SciencesOregon State UniversityCorvallisORUSA
- Linus Pauling InstituteOregon State UniversityCorvallisORUSA
| | - Claudia S. Maier
- Department of ChemistryOregon State UniversityCorvallisORUSA
- Linus Pauling InstituteOregon State UniversityCorvallisORUSA
| |
Collapse
|
17
|
Mendoza J, Carlson G, Nath P, Quinn J. P100 A REVIEW OF ADHERENCE WITH SUBCUTANEOUS IMMUNOTHERAPY (SCIT) IN HEALTHCARE SYSTEM WITHOUT OUT-OF-POCKET PATIENT EXPENSES. Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Parvizi J, Kamousi B, Karunakaran S, Quinn J, Woo R. 109 Rapid Response Electroencephalograph With Artificial Intelligence for Diagnosing Seizures and Highly Epileptiform Patterns in Emergency Medicine. Ann Emerg Med 2020. [DOI: 10.1016/j.annemergmed.2020.09.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
Pfaff A, Bubb V, Quinn J, Koks S. Polymorphic reference SVAs are associated with Parkinson's Disease progression markers and differential gene expression in the PPMI cohort. Parkinsonism Relat Disord 2020. [DOI: 10.1016/j.parkreldis.2020.06.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Stuart S, Morris R, Giritharan A, Quinn J, Nutt JG, Mancini M. Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy. Mov Disord 2020; 35:2019-2027. [PMID: 32830901 DOI: 10.1002/mds.28214] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2020] [Revised: 06/10/2020] [Accepted: 06/15/2020] [Indexed: 12/25/2022] Open
Abstract
Degradation of striatal dopamine in Parkinson's disease (PD) may initially be supplemented by increased cognitive control mediated by cholinergic mechanisms. Shift to cognitive control of walking can be quantified by prefrontal cortex activation. Levodopa improves certain aspects of gait and worsens others, and cholinergic augmentation influence on gait and prefrontal cortex activity remains unclear. This study examined dopaminergic and cholinergic influence on gait and prefrontal cortex activity while walking in PD. A single-site, randomized, double-blind crossover trial examined effects of levodopa and donepezil in PD. Twenty PD participants were randomized, and 19 completed the trial. Participants were randomized to either levodopa + donepezil (5 mg) or levodopa + placebo treatments, with 2 weeks with treatment and a 2-week washout. The primary outcome was change in prefrontal cortex activity while walking, and secondary outcomes were change in gait and dual-task performance and attention. Levodopa decreased prefrontal cortex activity compared with off medication (effect size, -0.51), whereas the addition of donepezil reversed this decrease. Gait speed and stride length under single- and dual-task conditions improved with combined donepezil and levodopa compared with off medication (effect size, 1 for gait speed and 0.75 for stride length). Dual-task reaction time was quicker with levodopa compared with off medication (effect size, -0.87), and accuracy improved with combined donepezil and levodopa (effect size, 0.47). Cholinergic therapy, specifically donepezil 5 mg/day for 2 weeks, can alter prefrontal cortex activity when walking and improve secondary cognitive task accuracy and gait in PD. Further studies will investigate whether higher prefrontal cortex activity while walking is associated with gait changes. © 2020 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Samuel Stuart
- Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA.,Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle upon Tyne, UK
| | - Rosie Morris
- Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA.,Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle upon Tyne, UK
| | - Andrew Giritharan
- Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA
| | - Joseph Quinn
- Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA
| | - John G Nutt
- Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA
| | - Martina Mancini
- Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA
| |
Collapse
|
21
|
O'Connor-Byrne N, Quinn J, Glavey SV, Lavin M, Brett F, Murphy PT. Venetoclax for chronic lymphocytic leukemia associated immune thrombocytopenia following recovery from progressive multifocal leukoencephalopathy. Leuk Res 2020; 95:106390. [PMID: 32526595 DOI: 10.1016/j.leukres.2020.106390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 05/10/2020] [Accepted: 05/23/2020] [Indexed: 11/17/2022]
Affiliation(s)
| | - J Quinn
- Beaumont Hospital, Ireland; Department of Medicine, Royal College of Surgeons in Ireland, Ireland
| | - S V Glavey
- Beaumont Hospital, Ireland; Department of Molecular Medicine, Royal College of Surgeons in Ireland, Ireland
| | - M Lavin
- Beaumont Hospital, Ireland; Irish Centre of Vascular Biology, Ireland
| | | | | |
Collapse
|
22
|
Mendoza J, Infante A, Nath P, Quinn J, Freeman T, Amornruk N. M262 A NOVEL ACTIVATION INDUCED CYTIDINE DEAMINASE MUTATION IN AN ADULT WITH HYPER-IGM SYNDROME. Ann Allergy Asthma Immunol 2019. [DOI: 10.1016/j.anai.2019.08.367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
23
|
Grill JD, Kwon J, Teylan MA, Pierce A, Vidoni ED, Burns JM, Lindauer A, Quinn J, Kaye J, Gillen DL, Nan B. Retention of Alzheimer Disease Research Participants. Alzheimer Dis Assoc Disord 2019; 33:299-306. [PMID: 31567302 PMCID: PMC6878201 DOI: 10.1097/wad.0000000000000353] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Participant retention is important to maintaining statistical power, minimizing bias, and preventing scientific error in Alzheimer disease and related dementias research. METHODS We surveyed representative investigators from NIH-funded Alzheimer's Disease Research Centers (ADRC), querying their use of retention tactics across 12 strategies. We compared survey results to data from the National Alzheimer's Coordinating Center for each center. We used a generalized estimating equation with independent working covariance model and empirical standard errors to assess relationships between survey results and rates of retention, controlling for participant characteristics. RESULTS Twenty-five (83%) responding ADRCs employed an average 42 (SD=7) retention tactics. In a multivariable model that accounted for participant characteristics, the number of retention tactics used by a center was associated with participant retention (odds ratio=1.68, 95% confidence interval: 1.42, 1.98; P<0.001 for the middle compared with the lowest tertile survey scores; odds ratio=1.59, 95% confidence interval: 1.30, 1.94; P<0.001 for the highest compared with the lowest tertile survey scores) at the first follow-up visit. Participant characteristics such as normal cognition diagnosis, older age, higher education, and Caucasian race were also associated with higher retention. CONCLUSIONS Retention in clinical research is more likely to be achieved by employing a variety of tactics.
Collapse
Affiliation(s)
- Joshua D. Grill
- Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, California
- Institute for Clinical and Translational Science, University of California, Irvine, Irvine, California
- Department of Psychiatry and Human Behavior, University of California, Irvine, Irvine, California
- Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California
| | - Jimmy Kwon
- Department of Statistics, University of California, Irvine, Irvine, California
| | - Merilee A. Teylan
- National Alzheimer’s Coordinating Center, University of Washington, Seattle Washington
| | - Aimee Pierce
- Layton Center on Aging and Alzheimer’s Disease, Oregon Health & Science University, Portland, Oregon
| | - Eric D. Vidoni
- University of Kansas Alzheimer’s Disease Center, Fairway, Kansas
| | - Jeffrey M. Burns
- University of Kansas Alzheimer’s Disease Center, Fairway, Kansas
| | - Allison Lindauer
- Layton Center on Aging and Alzheimer’s Disease, Oregon Health & Science University, Portland, Oregon
| | - Joseph Quinn
- Layton Center on Aging and Alzheimer’s Disease, Oregon Health & Science University, Portland, Oregon
| | - Jeff Kaye
- Layton Center on Aging and Alzheimer’s Disease, Oregon Health & Science University, Portland, Oregon
| | - Daniel L. Gillen
- Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, California
- Department of Statistics, University of California, Irvine, Irvine, California
| | - Bin Nan
- Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, California
- Department of Statistics, University of California, Irvine, Irvine, California
| |
Collapse
|
24
|
Goodman C, Popovic J, Quinn J, Echevarria N, Smith A, Skocypec H, Paunesku T, Woloschak G. Nuclear Delivery of Radiosensitizing EGFR-Targeted Nanoparticles Is Abrogated in Isogenic Cervical Cancer Cell Lines Following Mutagenesis of the Ligand Binding Domain. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Comerford C, McKey S, Wallace N, McArdle O, Faul C, Glavey S, Sargent J, Thornton P, Murphy PT, Quinn J. Solitary Plasmacytoma Management and Outcomes. Ir Med J 2019; 112:952. [PMID: 31538440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Affiliation(s)
| | | | - N Wallace
- St Luke’s Radiation Oncology Network, Dublin
| | - O McArdle
- St Luke’s Radiation Oncology Network, Dublin
| | - C Faul
- St Luke’s Radiation Oncology Network, Dublin
| | | | | | | | | | | |
Collapse
|
26
|
Bowman G, Gouskova N, Dodge H, Donohue J, Bichsel A, Silbert L, Quinn J, Kaye J. Pre-Analytical and Within-Person Reproducibility of Nutritional Metabolomics over 2 Years in Elders at Risk for Dementia (P18-121-19). Curr Dev Nutr 2019. [DOI: 10.1093/cdn/nzz039.p18-121-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Objectives
Nutritional metabolomics to objectively assess dietary intake in aging permit the opportunity to circumvent measurement errors that accompany subjective means of dietary assessment. At the same time, they may offer insights into mechanisms of action and metabolic disturbances that are actionable targets for modulation through diet in hopes of disease prevention and treatment. However, prior to more broad deployment the pre-analytical and temporal variation over time should be documented in order to design and interpret epidemiological studies properly. We quantified and examined 155 nutrient biomarkers and metabolites selected for their potential relevance to dementia.
Methods
Blood samples from three time points, spanning a 2-year period, were obtained from older adults participating in the NIA-Layton Oregon Alzheimer's Disease Center's Nutrition and Brain Aging Study (NBAS). Blood samples were batched randomly across three time points for quantification of blood amino acids, minerals, water and fat-soluble micronutrients, lipids, one carbon, and kynurenine pathway metabolites using a variety of methods including, tandem mass spectrometry. Pre-analytical coefficients of variation (CV) were calculated for all the biomarkers and intraclass correlation coefficients (ICC) were calculated to evaluate the within-person reproducibility in a subset of 137 participants.
Results
The mean baseline age of the analytic sample (n = 137) was 85.6 (± 8.3, 57 - 101 years), 70% are female, 21% carry the ApoEe4 allele and MMSE was 28.3 (± 1.78). The pre-analytical CVs ranged from 0.9% to 55.0% and the ICC ranged from 0 to 0.87 (25%-tile/median/75%-tile 0.41/0.54/0.66). Twenty four % had ICC < 0.40, 66% had ICC 0.40 −0.75 and 10% had ICC > 0.75.
Conclusions
The pre-analytical and within-person reproducibility of nutritional metabolomics in aging ranges widely. The majority can reliably estimate average concentrations over a 2 year period from a single time point and the biomarkers with ICC's above 0.40 can be used for correction of measurement error and those below 0.40 should consider multiple samples per subject and exploring the methodological and biological explanation for the variation over time.
Funding Sources
Nestle Institute of Health Sciences, Hinda and Arthur Marcus Institute for Aging Research, NIA-Layton Aging & Alzheimer's Disease Center (P30AGO8017).
Collapse
Affiliation(s)
- Gene Bowman
- Marcus Institute for Aging Research/Harvard Medical School
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Peterson B, Armstrong M, Galasko D, Galvin JE, Goldman J, Irwin D, Paulson H, Kaufer D, Leverenz J, Lunde A, McKeith IG, Siderowf A, Taylor A, Amodeo K, Barrett M, Domoto-Reilly K, Duda J, Gomperts S, Graff-Radford N, Holden S, Honig L, Huddleston D, Lippa C, Litvan I, Manning C, Marder K, Moussa C, Onyike C, Pagan F, Pantelyat A, Pelak V, Poston K, Quinn J, Richard I, Rosenthal LS, Sabbagh M, Scharre D, Sha S, Shill H, Torres-Yaghi Y, Christie T, Graham T, Richards I, Koehler M, Boeve B. Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. Alzheimers Res Ther 2019; 11:23. [PMID: 30867052 PMCID: PMC6417280 DOI: 10.1186/s13195-019-0476-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
Abstract
The first Lewy Body Dementia Association (LBDA) Research Centers of Excellence (RCOE) Investigator’s meeting was held on December 14, 2017, in New Orleans. The program was established to increase patient access to clinical experts on Lewy body dementia (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), and to create a clinical trials-ready network. Four working groups (WG) were created to pursue the LBDA RCOE aims: (1) increase access to high-quality clinical care, (2) increase access to support for people living with LBD and their caregivers, (3) increase knowledge of LBD among medical and allied (or other) professionals, and (4) create infrastructure for a clinical trials-ready network as well as resources to advance the study of new therapeutics.
Collapse
Affiliation(s)
| | | | | | | | | | - David Irwin
- University of Pennsylvania, Philadelphia, USA
| | | | | | | | - Angela Lunde
- Mayo Clinic campus, 200 1st Street SW, Rochester, MN, 55905, USA
| | | | | | | | | | | | | | - John Duda
- University of Pennsylvania, Philadelphia, USA
| | | | | | | | | | | | - Carol Lippa
- Thomas Jefferson University, Philadelphia, USA
| | | | | | | | - Charbel Moussa
- Georgetown University Medical Center, Washington, D.C., USA
| | | | - Fernando Pagan
- Georgetown University Medical Center, Washington, D.C., USA
| | | | | | | | - Joseph Quinn
- Oregon Health & Science University, Portland, USA
| | | | | | | | | | | | | | | | | | - Todd Graham
- Lewy Body Dementia Association, Lilburn, USA
| | | | | | - Brad Boeve
- Mayo Clinic campus, 200 1st Street SW, Rochester, MN, 55905, USA.
| |
Collapse
|
28
|
Edwards J, Baillie G, Quinn J, Monreno R, Banerjee S, Tomkinson N, MacKay S, De La Vega L. Abstract P3-10-10: DYRK2 is a novel therapeutic target in ER negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-10-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Dual specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) belongs to a family of CMGC kinases that function as modulators of different downstream pathways that allow cells to cope with hypoxia, DNA damage and various stress signals. Additionally, DYRK2 has been implicated in various human cancers with both pro- and anti-tumour roles, which are probably cancer type- and cell type-dependent. Furthermore, studies show that DYRK2 is involved in epithelial-mesenchymal transition, hence suggesting a role in tumour metastasis. The current study investigates the prognostic role of DYRK2 in breast cancer and investigates its potential as a novel therapeutic target.
Methods
Immunohistochemistry was employed to investigate if nuclear expression of DYRK2 was associated with clinical outcome measures in a cohort of 715 patients. Expression was determined using the weighted histoscore method. Antibody specificity was confirmed in paraffin embedded cell pellets +/- DYRK2 silencing. Cell counts in parental and CRISPR-mediated DYRK2 knocked-out MDA-MB-468 and MDA-MB-231 cells (ER, PR, HER2, AR negative) were measured using Alamar Blue; NSGTMmice (n=8) were injected subcutaneously with MDA-MDB-231 with or without DYRK2 depletion to assess tumour growth in vivo.
Results
In a cohort of 715 patients, median follow-up was 160 months with 155 breast cancer deaths and 135 deaths due to other causes. The majority of patients were over 50 years of age (71%), had ductal carcinoma (88%), tumours <20mm in size (56%) and node negative disease (57%). 489 patients had ER positive disease, 226 had ER negative disease and of these 148 had TN (triple-negative) disease. DYRK2 expression was observed in the cell cytoplasm and nucleus and ranged from 3 to 200 weighted histoscore units (WHS) and ROC analysis was used to determine cut-offs, tumours with a cytoplasmic and nuclear WHS <145 were classified as low expression and tumours with a cytoplasmic and nuclear WHS >145 were classified as high expression. In the full cohort (p=0.087) and ER negative (p=0.066) cohort DYRK2 was not associated with cancer specific survival. However in TN disease high DYRK2 expression was associated with cancer specific survival (p=0.012, mean survival 145 months versus 107 months). This was potentiated in patients with ER, PR, HER2, AR negative disease (p=0.005, mean survival 166 months versus 100 months) and independent in multivariate analysis with age, histological tumour type, tumour size tumour grad, nodal status, ki67 index, chemotherapy, radiotherapy and recurrence (p=0.13, HR 3.920). Following this observation, patients with ER, AR negative disease were investigated and again high DYRK2 expression was associated with cancer specific survival (p=0.0003, mean survival 163 months versus 86 months) and was independent when combined in multivariate analysis (p=0.001, HR 4.154).
To investigate if DYRK2 was a potential target in TN breast cancer, the effect of silencing DYRK2 was investigated. CRISPR-mediated DYRK2 depletion impeded cell proliferation in TN cell-lines and markedly reduced tumour burden in mouse MDA-MDB-231 xenografts (p<0.0001).
Conclusions
Our studies indicate that DYRK2 is indeed a potential therapeutic target for patients with TN breast cancer or ER, AR negative breast cancer.
Citation Format: Edwards J, Baillie G, Quinn J, Monreno R, Banerjee S, Tomkinson N, MacKay S, De La Vega L. DYRK2 is a novel therapeutic target in ER negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-10-10.
Collapse
Affiliation(s)
- J Edwards
- University of Glasgow, Glasgow, United Kingdom; University of Dundee, Dundee, United Kingdom; University of California San Diego, La Jolla, CA; University of Strathclyde, Glasgow, United Kingdom
| | - G Baillie
- University of Glasgow, Glasgow, United Kingdom; University of Dundee, Dundee, United Kingdom; University of California San Diego, La Jolla, CA; University of Strathclyde, Glasgow, United Kingdom
| | - J Quinn
- University of Glasgow, Glasgow, United Kingdom; University of Dundee, Dundee, United Kingdom; University of California San Diego, La Jolla, CA; University of Strathclyde, Glasgow, United Kingdom
| | - R Monreno
- University of Glasgow, Glasgow, United Kingdom; University of Dundee, Dundee, United Kingdom; University of California San Diego, La Jolla, CA; University of Strathclyde, Glasgow, United Kingdom
| | - S Banerjee
- University of Glasgow, Glasgow, United Kingdom; University of Dundee, Dundee, United Kingdom; University of California San Diego, La Jolla, CA; University of Strathclyde, Glasgow, United Kingdom
| | - N Tomkinson
- University of Glasgow, Glasgow, United Kingdom; University of Dundee, Dundee, United Kingdom; University of California San Diego, La Jolla, CA; University of Strathclyde, Glasgow, United Kingdom
| | - S MacKay
- University of Glasgow, Glasgow, United Kingdom; University of Dundee, Dundee, United Kingdom; University of California San Diego, La Jolla, CA; University of Strathclyde, Glasgow, United Kingdom
| | - L De La Vega
- University of Glasgow, Glasgow, United Kingdom; University of Dundee, Dundee, United Kingdom; University of California San Diego, La Jolla, CA; University of Strathclyde, Glasgow, United Kingdom
| |
Collapse
|
29
|
O'Connor-Byrne N, Glavey S, Tudor R, Murphy P, Thompson CJ, Quinn J. Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma. Exp Hematol Oncol 2019; 8:4. [PMID: 30733892 PMCID: PMC6359864 DOI: 10.1186/s40164-019-0128-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Accepted: 01/25/2019] [Indexed: 11/26/2022] Open
Abstract
The development of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) is well recognised in multiple myeloma (MM). SIADH, due to either MM or Bortezomib can be hazardous as severe hyponatremia may develop if large volumes of hypotonic intravenous fluid are used as an adjunct to chemotherapy. We report a case of Bortezomib-induced SIADH, in whom the use of tolvaptan, a vasopressin receptor-2 antagonist, permitted the continuation of triple combination anti-MM therapy with lenalidomide, Bortezomib and dexamethasone (RVD) in a female with aggressive disease, without the development of hyponatremia. Our patient had a rapid relapse, in which the use of Bortezomib as part of an RVD regimen was life-saving. The use of tolvaptan allowed continuation of therapy that is usually halted in other similarly reported cases. This case highlights the possible use of vaptans, which allows an aquaresis to occur by blocking the antidiuretic effects of vasopressin, as a treatment for Bortezomib-induced hyponatremia.
Collapse
Affiliation(s)
- N O'Connor-Byrne
- 1Academic Department of Haematology, Coleman Byrne Unit, Beaumont Hospital/RCSI Medical School, Dublin 9, Ireland
| | - S Glavey
- 1Academic Department of Haematology, Coleman Byrne Unit, Beaumont Hospital/RCSI Medical School, Dublin 9, Ireland
| | - R Tudor
- 2Academic Department of Endocrinology, Beaumont Hospital/RCSI Medical School, Dublin, Ireland
| | - P Murphy
- 1Academic Department of Haematology, Coleman Byrne Unit, Beaumont Hospital/RCSI Medical School, Dublin 9, Ireland
| | - C J Thompson
- 2Academic Department of Endocrinology, Beaumont Hospital/RCSI Medical School, Dublin, Ireland
| | - J Quinn
- 1Academic Department of Haematology, Coleman Byrne Unit, Beaumont Hospital/RCSI Medical School, Dublin 9, Ireland
| |
Collapse
|
30
|
Hendershott TR, Zhu D, Llanes S, Zabetian CP, Quinn J, Edwards KL, Leverenz JB, Montine T, Cholerton B, Poston KL. Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease. Mov Disord 2018; 34:285-291. [PMID: 30776152 DOI: 10.1002/mds.27575] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2018] [Revised: 10/24/2018] [Accepted: 10/26/2018] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Clinicians and researchers commonly use global cognitive assessments to screen for impairment. Currently there are no published studies directly comparing the sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. The objective of this study was to identify the relative sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. METHODS The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 were administered to training and validation cohorts. Cutoff scores were determined within the training cohort (n = 85) to optimize sensitivity and specificity for cognitive impairment and were applied to an independent validation cohort (n = 521). RESULTS The Montreal Cognitive Assessment was consistently sensitive across training and validation cohorts (90.0% and 80.3%, respectively), whereas the Mattis Dementia Rating Scale-2 was not (87.5% and 60.3%, respectively). In individual domains, the Montreal Cognitive Assessment remained sensitive to memory and visuospatial impairments (91.9% and 87.8%, respectively), whereas the Mattis Dementia Rating Scale-2 was sensitive to executive impairments (86.2%). CONCLUSION The Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 demonstrated individual strengths. Future work should focus on developing domain-specific cognitive screening tools for PD. © 2018 International Parkinson and Movement Disorder Society.
Collapse
Affiliation(s)
- Taylor R Hendershott
- Department of Psychological and Brain Sciences, Washington University, St. Louis, Missouri, USA
| | - Delphine Zhu
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA
| | - Seoni Llanes
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA
| | - Cyrus P Zabetian
- Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA.,Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA
| | - Joseph Quinn
- Department of Neurology, Oregon Health Sciences University, Portland, Oregon, USA
| | - Karen L Edwards
- Department of Epidemiology, University of California, Irvine School of Medicine, Irvine, California, USA
| | - James B Leverenz
- Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - Thomas Montine
- Department of Pathology, Stanford University School of Medicine, Stanford, California, USA
| | - Brenna Cholerton
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA
| | - Kathleen L Poston
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.,Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA
| |
Collapse
|
31
|
Seier M, Hiller A, Quinn J, Murchison C, Brodsky M, Anderson S. Alternating Thalamic Deep Brain Stimulation for Essential Tremor: A Trial to Reduce Habituation. Mov Disord Clin Pract 2018; 5:620-626. [PMID: 30637283 DOI: 10.1002/mdc3.12685] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2018] [Revised: 09/03/2018] [Accepted: 09/09/2018] [Indexed: 11/08/2022] Open
Abstract
Background DBS in the ventral intermediate nucleus (VIM) of the thalamus has been a revolutionary treatment for patients with essential tremor (ET) by reducing tremor. Unfortunately, some patients develop habituation to DBS and thus experience reduced efficacy and loss of tremor control. There are no standardized methods of addressing habituation to DBS. We propose alternating stimulation patterns as a way to reduce habituation. Methods This was a randomized, placebo-controlled trial for patients with VIM DBS for ET. Patients were randomized to either experimental treatment arm of alternating stimulation patterns on a weekly basis or standard care arm of continuous stimulation settings for 12 weeks. Primary outcome was change in the performance subscale of The Essential Tremor Rating Assessment Scale (TETRAS), which was performed at initial visit and 12-week follow-up. Secondary outcome included change in the activities of daily living subscale of TETRAS. Results Twenty-two patients were enrolled in the trial, and 16 were analyzed at follow-up. Experimental treatment subjects displayed sustained tremor control compared to standard care, as measured by the change in TETRAS performance subscale (-0.6 vs. 6.7 point change, respectively) with a 7.3 difference between the arms (P = 0.006). Conclusion Alternating stimulation patterns on a weekly basis for ET patients with VIM DBS reduced habituation in this pilot study. This study suggests that exposure to different stimulation groups may maintain better tremor control compared to constant stimulation parameters.
Collapse
Affiliation(s)
- Mara Seier
- Department of Neurological Sciences University of Nebraska Medical Center Omaha Nebraska USA
| | - Amie Hiller
- Northwest Parkinson Disease Research Education and Clinical Center, Portland VA Medical Center Portland Oregon USA.,Department of Neurology Oregon Health Sciences University Portland Oregon USA
| | - Joseph Quinn
- Northwest Parkinson Disease Research Education and Clinical Center, Portland VA Medical Center Portland Oregon USA.,Department of Neurology Oregon Health Sciences University Portland Oregon USA
| | - Charles Murchison
- Department of Biostatistics, School of Public Health University of Alabama at Birmingham Birmingham Alabama USA
| | - Matthew Brodsky
- Department of Neurology Oregon Health Sciences University Portland Oregon USA
| | - Shannon Anderson
- Department of Neurology Oregon Health Sciences University Portland Oregon USA
| |
Collapse
|
32
|
Szari S, Adams K, Quinn J, Stokes S, Sacha J, White K. CHARACTERISTICS OF VENOM ALLERGY AT INITIAL EVALUATION. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Roseweir AK, Kong CY, Park JH, Bennett L, Powell AGMT, Quinn J, van Wyk HC, Horgan PG, McMillan DC, Edwards J, Roxburgh CS. A novel tumor-based epithelial-to-mesenchymal transition score that associates with prognosis and metastasis in patients with Stage II/III colorectal cancer. Int J Cancer 2018; 144:150-159. [PMID: 29992570 DOI: 10.1002/ijc.31739] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Accepted: 06/13/2018] [Indexed: 12/11/2022]
Abstract
It is increasingly appreciated that host factors within the tumor center and microenvironment play a key role in dictating colorectal cancer (CRC) outcomes. As a result, the metastatic process has now been defined as a result of epithelial-mesenchymal transition (EMT). Establishment of the role of EMT within the tumor center and its effect on the tumor microenvironment would be beneficial for prognosis and therapeutic intervention in CRC. The present study assessed five immunohistochemical EMT markers within the tumor center on a 185 Stage II/III CRC patient tissue microarray. In 185 patients with CRC, cytoplasmic snail (HR 1.94 95% confidence interval [CI] 1.15-3.29, p = 0.012) and a novel combined EMT score (HR 3.86 95% CI 2.17-6.86, p < 0.001) were associated with decreased cancer-specific survival. The combined EMT score was also associated with increased tumor budding (p = 0.046), and systemic inflammation (p = 0.007), as well as decreased memory T-cells within the stroma (p = 0.030) and at the invasive margin (p = 0.035). Furthermore, the combined EMT score was associated with cancer-specific survival independent of TNM-stage (HR 4.12 95% CI 2.30-7.39, p < 0.001). In conclusion, a novel combined EMT score stratifies patient's survival in Stage II/III CRC and associates with key factors of tumor metastasis. Therefore, the combined EMT score could be used to identify patients at risk of micrometastases and who may benefit from standard adjuvant therapy, potentially in combination with EMT blockade.
Collapse
Affiliation(s)
- A K Roseweir
- School of Medicine, University of Glasgow, Glasgow, United Kingdom.,Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
| | - C Y Kong
- School of Medicine, University of Glasgow, Glasgow, United Kingdom
| | - J H Park
- School of Medicine, University of Glasgow, Glasgow, United Kingdom
| | - Lindsay Bennett
- Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
| | - A G M T Powell
- Department of Genetics and Cancer, University of Cardiff, Cardiff, United Kingdom
| | - J Quinn
- School of Medicine, University of Glasgow, Glasgow, United Kingdom
| | - H C van Wyk
- School of Medicine, University of Glasgow, Glasgow, United Kingdom
| | - P G Horgan
- School of Medicine, University of Glasgow, Glasgow, United Kingdom
| | - D C McMillan
- School of Medicine, University of Glasgow, Glasgow, United Kingdom
| | - Joanne Edwards
- Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
| | - C S Roxburgh
- School of Medicine, University of Glasgow, Glasgow, United Kingdom.,Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom
| |
Collapse
|
34
|
Besser L, Kukull W, Knopman DS, Chui H, Galasko D, Weintraub S, Jicha G, Carlsson C, Burns J, Quinn J, Sweet RA, Rascovsky K, Teylan M, Beekly D, Thomas G, Bollenbeck M, Monsell S, Mock C, Zhou XH, Thomas N, Robichaud E, Dean M, Hubbard J, Jacka M, Schwabe-Fry K, Wu J, Phelps C, Morris JC. Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 2018; 32:351-358. [PMID: 30376508 PMCID: PMC6249084 DOI: 10.1097/wad.0000000000000279] [Citation(s) in RCA: 218] [Impact Index Per Article: 36.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Accepted: 09/04/2018] [Indexed: 11/26/2022]
Abstract
INTRODUCTION In 2015, the US Alzheimer's Disease Centers (ADC) implemented Version 3 of the Uniform Data Set (UDS). This paper describes the history of Version 3 development and the UDS data that are freely available to researchers. METHODS UDS Version 3 was developed after years of coordination between the National Institute on Aging-appointed Clinical Task Force (CTF), clinicians from ∼30 ADCs, and the National Alzheimer's Coordinating Center (NACC). The CTF recognized the need for updates to align with the state of the science in dementia research, while being flexible to the diverse needs and diseases studied at the ADCs. Version 3 also developed a nonproprietary neuropsychological battery. RESULTS This paper focuses on the substantial Version 3 changes to the UDS forms related to clinical diagnosis and characterization of clinical symptoms to match updated consensus-based diagnostic criteria. Between March 2015 and March 2018, 4820 participants were enrolled using UDS Version 3. Longitudinal data were available for 25,337 of the 37,568 total participants using all UDS versions. DISCUSSION The results from utilization of the UDS highlight the possibility for numerous research institutions to successfully collaborate, produce, and use standardized data collection instruments for over a decade.
Collapse
Affiliation(s)
- Lilah Besser
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
- Institute for Healthy Aging and Lifespan Studies and School of Urban and Regional Planning, Florida Atlantic University, Boca Raton, FL
| | - Walter Kukull
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | | | - Helena Chui
- Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, Los Angeles
| | - Douglas Galasko
- Department of Neurosciences, University of California San Diego, La Jolla, CA
| | - Sandra Weintraub
- Departments of Psychiatry and Neurology, and Cognitive Neurology and Alzheimer’s Disease Center, Northwestern University Feinberg School of Medicine, Chicago, IL
| | - Gregory Jicha
- Department of Neurology, University of Kentucky, Lexington, KY
| | - Cynthia Carlsson
- Department of Medicine, University of Wisconsin School of Medicine and Public Health; Geriatric Research, Education and Clinical Center, Madison VA Hospital, Madison, WI
| | - Jeffrey Burns
- Department of Neurology, School of Medicine, University of Kansas, Kansas City, KS
| | - Joseph Quinn
- Department of Neurology, School of Medicine, Oregon Health & Science University, Portland, OR
| | - Robert A. Sweet
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia
| | - Katya Rascovsky
- Department of Psychiatry, University of Pittsburgh School of Medicine
- Department of Neurology, University of Pittsburgh School of Medicine
- Mental Illness Research, Education, and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA
| | - Merilee Teylan
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | - Duane Beekly
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | - George Thomas
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | - Mark Bollenbeck
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | - Sarah Monsell
- Center for Biomedical Statistics, University of Washington, Seattle, WA
| | - Charles Mock
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | - Xiao Hua Zhou
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | - Nicole Thomas
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | - Elizabeth Robichaud
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | - Margaret Dean
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | - Janene Hubbard
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | - Mary Jacka
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | - Kristen Schwabe-Fry
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | - Joylee Wu
- Department of Epidemiology, National Alzheimer’s Coordinating Center, University of Washington, Seattle, WA
| | | | | | - John C. Morris
- Department of Neurology, Washington University School of Medicine, St. Louis, MO
| |
Collapse
|
35
|
Bledsoe J, Stevens S, Woller S, Brown I, Madsen T, Quinn J, Johnson S, Kelly C, Elliott C, Haug P. 375 Comparison of Electronic Clinical Decision Support for the Diagnosis of Suspected Pulmonary Embolism in Three Health Care Systems. Ann Emerg Med 2018. [DOI: 10.1016/j.annemergmed.2018.08.380] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Archer A, Benbow W, Bird R, Brose R, Buchovecky M, Buckley J, Bugaev V, Connolly M, Cui W, Daniel M, Feng Q, Finley J, Fortson L, Furniss A, Gillanders G, Hütten M, Hanna D, Hervet O, Holder J, Hughes G, Humensky T, Johnson C, Kaaret P, Kar P, Kelley-Hoskins N, Kertzman M, Kieda D, Krause M, Krennrich F, Kumar S, Lang M, Lin T, Maier G, McArthur S, Moriarty P, Mukherjee R, O’Brien S, Ong R, Otte A, Petrashyk A, Pohl M, Pueschel E, Quinn J, Ragan K, Reynolds P, Richards G, Roache E, Rulten C, Sadeh I, Santander M, Sembroski G, Staszak D, Sushch I, Wakely S, Wells R, Wilcox P, Wilhelm A, Williams D, Williamson T, Zitzer B. Measurement of cosmic-ray electrons at TeV energies by VERITAS. Int J Clin Exp Med 2018. [DOI: 10.1103/physrevd.98.062004] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
37
|
Walsh I, Quinn J, Spencer A, Noble H. AnArtomy: Arts, Anatomy and Medicine - Human Beings Being Human. MedEdPublish (2016) 2018; 7:204. [PMID: 38074618 PMCID: PMC10701823 DOI: 10.15694/mep.2018.0000204.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2024] Open
Abstract
This article was migrated. The article was marked as recommended. Background The study of anatomy underpins medical education and is an important facet of clinical practice in various diverse disciplines. We explored the dynamic relationship between arts, anatomy and medicine, along the continuum axis of anatomy, medicine, healthcare and art. Aims 1. to foster and gauge artistic and creative expression within the context of medical science and practice. 2. to generate representative artwork examining the relationship between art, medicine and healthcare. Methods Two purposefully open and expressive creative workshops were held within the cadaveric dissection laboratory of the Queen's University Department of Anatomy; with awide variety of artistic substrates available for faculty and student participants. Themes included: the relationship between art and medicine, the impact art and science have upon each other and the effects of creativity on wellbeing. Accompanying questionnaires included a quantification of perceived relationships between art and medicine; with an estimation of connectedness to feelings. Qualitative items within each questionnaire also addressed key humanistic questions. Comparative analysis of quantitative results was by Student's t-testing; statistical significance being p values <0.05. Results, Summary and Conclusions There was a statistically significant increase in "connectedness to feelings" amongst participants over the course of the workshop. There was a trend for participants to agree or strongly agree that art and medicine were important to each other. Qualitative responses changed from specific, task-oriented hopes to responses more aligned with social/gregarious themes and those related to higher order functioning. Humanistic responses changed across the entire group from a largely fixed inclusion of the concept of emotions to broader, more altruistic visions; inclusive of communal, social views. There was a noticeable shift in emphasis from succinctly defined descriptive terms to more expressive terms; reflective and inclusive of caring, holistic practice. The most arresting and compelling results were those of the resulting representative artwork.
Collapse
|
38
|
Quinn J, Hemmerling J, Linic S. Maximizing Solar Water Splitting Performance by Nanoscopic Control of the Charge Carrier Fluxes across Semiconductor–Electrocatalyst Junctions. ACS Catal 2018. [DOI: 10.1021/acscatal.8b01929] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Joseph Quinn
- Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - John Hemmerling
- Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Suljo Linic
- Department of Chemical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States
| |
Collapse
|
39
|
Gustafson L, Jones R, Dufour-Zavala L, Jensen E, Malinak C, McCarter S, Opengart K, Quinn J, Slater T, Delgado A, Talbert M, Garber L, Remmenga M, Smeltzer M. Expert Elicitation Provides a Rapid Alternative to Formal Case-Control Study of an H7N9 Avian Influenza Outbreak in the United States. Avian Dis 2018; 62:201-209. [DOI: 10.1637/11801-011818-reg.1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- L. Gustafson
- United States Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary Services, Center for Epidemiology and Animal Health, 2150 Centre Avenue, Fort Collins, CO 80526
| | - R. Jones
- United States Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary Services, Center for Epidemiology and Animal Health, 2150 Centre Avenue, Fort Collins, CO 80526
| | - L. Dufour-Zavala
- Georgia Poultry Laboratory Network, 3235 Abit Massey Way, Gainesville, GA 30507
| | - E. Jensen
- Aviagen North America, 920 Explorer Boulevard NW, Huntsville, AL 35806
| | - C. Malinak
- Peco Foods, Inc., 145 2nd Avenue NW, Gordo, AL 35466
| | - S. McCarter
- Tyson Foods, Inc., 649 Sherwood Road NE, Atlanta, GA 30324
| | - K. Opengart
- Global Sustainability & Animal Welfare, Keystone Foods, 6767 Old Madison Pike, Huntsville, AL 35806
| | - J. Quinn
- United States Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary Services, District 1 Field Office for North Carolina–West Virginia, 920 Main Campus Drive, Suite 200, Raleigh, NC 27606
| | - T. Slater
- Hinton Mitchem Poultry Diagnostic Laboratory, Alabama Department of Agriculture and Industries, P.O. Box 409, Hanceville, AL 35077
| | - A. Delgado
- United States Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary Services, Center for Epidemiology and Animal Health, 2150 Centre Avenue, Fort Collins, CO 80526
| | - M. Talbert
- United States Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary Services, Center for Epidemiology and Animal Health, 2150 Centre Avenue, Fort Collins, CO 80526
| | - L. Garber
- United States Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary Services, Center for Epidemiology and Animal Health, 2150 Centre Avenue, Fort Collins, CO 80526
| | - M. Remmenga
- United States Department of Agriculture, Animal and Plant Health Inspection Service, Veterinary Services, Center for Epidemiology and Animal Health, 2150 Centre Avenue, Fort Collins, CO 80526
| | - M. Smeltzer
- Georgia Poultry Laboratory Network, 3235 Abit Massay Way, Gainesville, GA 30507
| |
Collapse
|
40
|
Salen G, DeBarber A, Eichler F, Casaday L, Jayadev S, Kisanuki Y, Lekprasert P, Malloy M, Ramdhani R, Zialka P, Quinn J, Su K, Geller A, Diffenderfer M, Schaefer E. The Diagnosis and Treatment of Cerebrotendinous Xanthomatosis. J Clin Lipidol 2018. [DOI: 10.1016/j.jacl.2018.03.044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
41
|
Gray NE, Alcazar Magana A, Lak P, Wright KM, Quinn J, Stevens JF, Maier CS, Soumyanath A. Centella asiatica - Phytochemistry and mechanisms of neuroprotection and cognitive enhancement. Phytochem Rev 2018; 17:161-194. [PMID: 31736679 PMCID: PMC6857646 DOI: 10.1007/s11101-017-9528-y] [Citation(s) in RCA: 89] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/30/2017] [Accepted: 08/17/2017] [Indexed: 05/18/2023]
Abstract
This review describes in detail the phytochemistry and neurological effects of the medicinal herb Centella asiatica (L.) Urban. C. asiatica is a small perennial plant that grows in moist, tropical and sub-tropical regions throughout the world. Phytochemicals identified from C. asiatica to date include isoprenoids (sesquiterpenes, plant sterols, pentacyclic triterpenoids and saponins) and phenylpropanoid derivatives (eugenol derivatives, caffeoylquinic acids, and flavonoids). Contemporary methods for fingerprinting and characterization of compounds in C. asiatica extracts include liquid chromatography and/or ion mobility spectrometry in conjunction with high-resolution mass spectrometry. Multiple studies in rodent models, and a limited number of human studies support C. asiatica's traditional reputation as a cognitive enhancer, as well as its anxiolytic and anticonvulsant effects. Neuroprotective effects of C.asiatica are seen in several in vitro models, for example against beta amyloid toxicity, and appear to be associated with increased mitochondrial activity, improved antioxidant status, and/or inhibition of the pro-inflammatory enzyme, phospholipase A2. Neurotropic effects of C. asiatica include increased dendritic arborization and synaptogenesis, and may be due to modulations of signal transduction pathways such as ERK1/2 and Akt. Many of these neurotropic and neuroprotective properties of C.asiatica have been associated with the triterpene compounds asiatic acid, asiaticoside and madecassoside. More recently, caffeoylquinic acids are emerging as a second important group of active compounds in C. asiatica, with the potential of enhancing the Nrf2-antioxidant response pathway. The absorption, distribution, metabolism and excretion of the triterpenes, caffeoylquinic acids and flavonoids found in C. asiatica have been studied in humans and animal models, and the compounds or their metabolites found in the brain. This review highlights the remarkable potential for C. asiatica extracts and derivatives to be used in the treatment of neurological conditions, and considers the further research needed to actualize this possibility.
Collapse
Affiliation(s)
- Nora E. Gray
- Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239
| | | | - Parnian Lak
- Department of Chemistry, Oregon State University, Corvallis, Oregon 97331
| | - Kirsten M. Wright
- Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239
| | - Joseph Quinn
- Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239
- Department of Neurology and Parkinson’s Disease Research Education and Clinical Care Center (PADRECC),
Portland Veterans Affairs Medical Center, Portland, OR, USA 97239
| | - Jan F. Stevens
- Department of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon 97331
- Linus Pauling Institute, Oregon State University, Corvallis, Oregon 97331
| | - Claudia S. Maier
- Department of Pharmaceutical Sciences, Oregon State University, Corvallis, Oregon 97331
- Linus Pauling Institute, Oregon State University, Corvallis, Oregon 97331
| | - Amala Soumyanath
- Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239
| |
Collapse
|
42
|
Mueller M, Wiley D, Tentler A, Bocko M, Chen L, Leibovici A, Quinn J, Shar A, Pentland AP, Horwitz CM. Is Home Health Technology Adequate for Proactive Self-care? Methods Inf Med 2018; 47:58-62. [DOI: 10.3414/me9101] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Summary
Objective:
To understand whether home health technology in the market and in development can satisfy the needs of patients and their non-professional caregivers for proactive support in managing health and chronic conditions in the home.
Methods:
A panel of clinical providers and technology researchers was assembled to examine whether home health technology addresses consumer-defined requirements for self-care devices. A lexicon of home care and self-care technology terms was then created. A global survey of home health technology for patients with heart disease and dementia was conducted. The 254 items identified were categorized by conditions treated, primary user, function, and purpose. A focus group of patients and caregivers was convened to describe their expectations of self-care technology. Items identified in the database were then assessed for these attributes.
Results:
Patients and family caregivers indicated a need for intelligent self-care technology which supports early diagnosis of health changes, intervention enablement, and improvement of communication quality among patients and the health care system. Of these, only intervention enablement was commonly found in the home health technology items identified.
Conclusions:
An opportunity exists to meet consumer self-care needs through increased research and development in intelligent self-care technology.
Collapse
|
43
|
Comerford CM, Morrell R, Johnson D, Javadpour M, Beausang A, Cryan J, Murphy P, Quinn J. Pituitary plasmacytoma—a rare presentation of multiple myeloma. Ir J Med Sci 2017; 187:349-350. [DOI: 10.1007/s11845-017-1690-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2017] [Accepted: 10/03/2017] [Indexed: 10/18/2022]
|
44
|
Quinn J, Palisoul M, Guo L, Fuh K. Inhibition of the Receptor Tyrosine Kinase AXL Sensitizes Uterine Serous Cancer to Paclitaxel via Increased Accumulation of Paclitaxel in Tumor Cells. Gynecol Oncol 2017. [DOI: 10.1016/j.ygyno.2017.07.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Langabeer SE, Haslam K, Kelly J, Quinn J, Morrell R, Conneally E. Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis. Clin Transl Oncol 2017; 20:420-423. [PMID: 28762112 DOI: 10.1007/s12094-017-1722-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Accepted: 07/24/2017] [Indexed: 12/15/2022]
Abstract
PURPOSE Chronic neutrophilic leukemia is a rare form of myeloproliferative neoplasm characterized by mature neutrophil hyperleukocytosis. The majority of patients harbor somatic mutations of CSF3R gene and are potentially amenable to targeted therapy with JAK inhibitors. The incidence and clinical significance of additional mutations requires clarification. MATERIALS AND METHODS A next-generation sequencing approach for myeloid malignancy-associated mutations was applied to diagnostic and matched blast crisis samples from four chronic neutrophilic leukemia patients. RESULTS Next-generation sequencing confirmed the CSF3R T618I in all patients with identification of concurrent SRSF2, SETBP1, NRAS and CBL mutations at diagnosis. At blast crisis, clonal evolution was evidenced by an increased CSF3R T618I allele frequency and by loss or acquisition of CBL and NRAS mutations. CONCLUSION The diagnostic utility of a targeted next-generation sequencing approach was clearly demonstrated with the identification of additional mutations providing the potential for therapeutic stratification of chronic neutrophilic leukemia patients.
Collapse
Affiliation(s)
- S E Langabeer
- Central Pathology Laboratory, Cancer Molecular Diagnostics, St. James's Hospital, Dublin 8, Ireland.
| | - K Haslam
- Central Pathology Laboratory, Cancer Molecular Diagnostics, St. James's Hospital, Dublin 8, Ireland
| | - J Kelly
- Department of Clinical Genetics, Our Lady's Children's Hospital, Dublin, Ireland
| | - J Quinn
- Department of Haematology, Beaumont Hospital, Dublin, Ireland
| | - R Morrell
- Department of Haematology, Letterkenny University Hospital, Letterkenny, Ireland
| | - E Conneally
- Department of Haematology, St. James's Hospital, Dublin, Ireland
| |
Collapse
|
46
|
Affiliation(s)
- J. Quinn
- Boston College, Chestnut Hill, Massachusetts,
| | - K. Cahill
- Center on Aging & Work at Boston College, Chestnut Hill, Massachusetts
| |
Collapse
|
47
|
O'Shea K J, Burke J, Murphy P, Quinn J. Adult attention deficit hyperactivity disorder and driving - risk, medication and fitness to drive. Ir Med J 2017; 110:592. [PMID: 28952682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Affiliation(s)
- J O'Shea K
- Department of Haematology, Beaumont Hospital, Dublin 9, Ireland
| | - J Burke
- Department of Surgery, Beaumont Hospital, Dublin 9, Ireland
| | - P Murphy
- Department of Haematology, Beaumont Hospital, Dublin 9, Ireland
| | - J Quinn
- Department of Haematology, Beaumont Hospital, Dublin 9, Ireland
| |
Collapse
|
48
|
Archambault S, Archer A, Benbow W, Bird R, Bourbeau E, Brantseg T, Buchovecky M, Buckley J, Bugaev V, Byrum K, Cerruti M, Christiansen J, Connolly M, Cui W, Daniel M, Feng Q, Finley J, Fleischhack H, Fortson L, Furniss A, Geringer-Sameth A, Griffin S, Grube J, Hütten M, Håkansson N, Hanna D, Hervet O, Holder J, Hughes G, Hummensky B, Johnson C, Kaaret P, Kar P, Kelley-Hoskins N, Kertzman M, Kieda D, Koushiappas S, Krause M, Krennrich F, Lang M, Lin T, McArthur S, Moriarty P, Mukherjee R, Nieto D, O’Brien S, Ong R, Otte A, Park N, Pohl M, Popkow A, Pueschel E, Quinn J, Ragan K, Reynolds P, Richards G, Roache E, Rulten C, Sadeh I, Santander M, Sembroski G, Shahinyan K, Smith A, Staszak D, Telezhinsky I, Trepanier S, Tucci J, Tyler J, Wakely S, Weinstein A, Wilcox P, Williams D, Zitzer B. Dark matter constraints from a joint analysis of dwarf Spheroidal galaxy observations with VERITAS. Int J Clin Exp Med 2017. [DOI: 10.1103/physrevd.95.082001] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
49
|
Abstract
BACKGROUND Identifying predictors of conversion to Alzheimer's disease (AD) is critically important for AD prevention and targeted treatment. OBJECTIVE To compare various clinical and biomarker trajectories for tracking progression and predicting conversion from amnestic mild cognitive impairment to probable AD. METHODS Participants were from the ADNI-1 study. We assessed the ability of 33 longitudinal biomarkers to predict time to AD conversion, accounting for demographic and genetic factors. We used joint modelling of longitudinal and survival data to examine the association between changes of measures and disease progression. We also employed time-dependent receiver operating characteristic method to assess the discriminating capability of the measures. RESULTS 23 of 33 longitudinal clinical and imaging measures are significant predictors of AD conversion beyond demographic and genetic factors. The strong phenotypic and biological predictors are in the cognitive domain (ADAS-Cog; RAVLT), functional domain (FAQ), and neuroimaging domain (middle temporal gyrus and hippocampal volume). The strongest predictor is ADAS-Cog 13 with an increase of one SD in ADAS-Cog 13 increased the risk of AD conversion by 2.92 times. CONCLUSION Prediction of AD conversion can be improved by incorporating longitudinal change information, in addition to baseline characteristics. Cognitive measures are consistently significant and generally stronger predictors than imaging measures.
Collapse
Affiliation(s)
- Kan Li
- Department of Biostatistics, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | - Wenyaw Chan
- Department of Biostatistics, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | | | - Joseph Quinn
- Department of Neurology, Oregon Health and Science University and Portland VA Medical Center, Portland, OR, USA
| | - Sheng Luo
- Department of Biostatistics, The University of Texas Health Science Center at Houston, Houston, TX, USA
| | | |
Collapse
|
50
|
Cooper CA, Jain N, Gallagher MD, Weintraub D, Xie SX, Berlyand Y, Espay AJ, Quinn J, Edwards KL, Montine T, Van Deerlin VM, Trojanowski J, Zabetian CP, Chen-Plotkin AS. Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. Ann Clin Transl Neurol 2016; 4:15-25. [PMID: 28078311 PMCID: PMC5221454 DOI: 10.1002/acn3.371] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Accepted: 10/04/2016] [Indexed: 01/11/2023] Open
Abstract
Objective Parkinson's disease (PD) presents clinically with several motor subtypes that exhibit variable treatment response and prognosis. Here, we investigated genetic variants for their potential association with PD motor phenotype and progression. Methods We screened 10 SNPs, previously associated with PD risk, for association with tremor‐dominant (TD) versus postural‐instability gait disorder (PIGD) motor subtypes. SNPs that correlated with the TD/PIGD ratio in a discovery cohort of 251 PD patients were then evaluated in a multi‐site replication cohort of 559 PD patients. SNPs associated with motor phenotype in both cross‐sectional cohorts were next evaluated for association with (1) rates of motor progression in a longitudinal subgroup of 230 PD patients and (2) brain alpha‐synuclein (SNCA) expression in the GTEx (Genotype‐Tissue Expression project) consortium database. Results Genotype at rs356182, near SNCA, correlated with the TD/PIGD ratio in both the discovery (Bonferroni‐corrected P = 0.04) and replication cohorts (P = 0.02). The rs356182 GG genotype was associated with a more tremor‐predominant phenotype and predicted a slower rate of motor progression (1‐point difference in annual rate of UPDRS‐III motor score change, P = 0.01). The rs356182 genotype was associated with SNCA expression in the cerebellum (P = 0.005). Interpretation Our study demonstrates that the GG genotype at rs356182 provides molecular definition for a clinically important endophenotype associated with (1) more tremor‐predominant motor phenomenology, (2) slower rates of motor progression, and (3) decreased brain expression of SNCA. Such molecularly defined endophenotyping in PD may benefit both clinical trial design and tailoring of clinical care as we enter the era of precision medicine.
Collapse
Affiliation(s)
- Christine A Cooper
- Department of Neurology Medical University of South Carolina Charleston South Carolina; Department of Neurology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania
| | - Nimansha Jain
- Department of Neurology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania
| | - Michael D Gallagher
- Department of Neurology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania
| | - Daniel Weintraub
- Department of Psychiatry Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania
| | - Sharon X Xie
- Department of Biostatistics and Epidemiology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania
| | - Yosef Berlyand
- Department of Neurology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania; Harvard Medical School Boston Massachusetts
| | - Alberto J Espay
- Department of Neurology University of Cincinnati Cincinnati Ohio
| | - Joseph Quinn
- Department of Neurology Oregon Health and Science University Portland Oregon
| | - Karen L Edwards
- Department of Epidemiology University of California Irvine Irvine California
| | - Thomas Montine
- Department of Pathology University of Washington Seattle Washington
| | - Vivianna M Van Deerlin
- Department of Pathology and Laboratory Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania
| | - John Trojanowski
- Department of Pathology and Laboratory Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania
| | - Cyrus P Zabetian
- Department of Neurology VA Puget Sound Health Care System University of Washington Seattle Washington
| | - Alice S Chen-Plotkin
- Department of Neurology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania
| |
Collapse
|